Method and composition for target analysis
OligoCASSEQ method enhances target molecule analysis by using barcoded oligonucleotide tags to detect up to 20 targets simultaneously, overcoming spectral limitations in fluorescence microscopy.
Patent Information
- Application Number
- KR1020227005970
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-07-30
- Filing Date
- 2020-07-30
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2040-07-30
AI Technical Summary
Existing methods in fluorescence microscopy are limited to visualizing only 4 to 5 targets simultaneously due to full-spectral limitations, making it difficult to analyze complex systems with more than five components or large target molecules like chromosomes.
The OligoCASSEQ method uses oligonucleotide tags (e.g., oligopaints) with barcoded cassettes that allow for the simultaneous detection of at least two targets, enabling the visualization of four or more targets by utilizing a 2-bit barcode, without requiring enzymes like ligases or polymerases, and employing shorter oligos.
This approach enables the simultaneous detection of up to 20 target molecules with single-cell resolution, surpassing conventional methods by allowing for more targets to be analyzed simultaneously and at a lower cost.
Smart Images

Figure 112022019823315-PCT00001_ABST
Abstract
Description
Technology Field
[0001] Cross-reference regarding related applications
[0002] This application claims the benefit under 35 USC § 119(e) of U.S. Provisional Application No. 62 / 880,216 filed on July 30, 2019, the contents of said Provisional Application are incorporated herein by reference in their entirety.
[0003] Government support
[0004] The present invention was made with government support under grant numbers GM123289 and HG008525 awarded by the National Institutes of Health. The government holds specific rights to the present invention.
[0005] Sequence list
[0006] The present application includes a list of sequences submitted in ASCII format via EFS-Web, the entirety of which is incorporated herein by reference. The said ASCII copy was created on July 27, 2020, named 002806-094580_SL.txt, and has a size of 1,055 bytes.
[0007] Technology field
[0008] The technology described in this specification relates to methods, systems, and compositions for analyzing, detecting, and / or visualizing target molecules. Background Technology
[0009] Visualization of targets at the cellular and subcellular levels typically utilizes fluorophores linked to detection molecules (e.g., antibodies, oligos, synthetic nucleic acids, etc.). Due to the full-spectral limitations of fluorescence microscopy, only 4 to 5 targets can be visualized simultaneously. However, for some applications, such as complex systems containing more than five components or large target molecules like chromosomes, it is necessary to visualize five or more targets simultaneously. Accordingly, there is a need for new methods capable of simultaneously detecting many targets or large regions of targets.
[0010] The technology described herein relates to methods, systems, and compositions for analyzing, detecting, and / or visualizing target molecules that provide the ability to visualize more targets at once than is possible with the prior art. For example, when detecting target biomolecules using fluorescent labels, the present method causes a detection probe using four colors to be localized to targets within a group, wherein the probes aggregate to different targets within a group that form a barcoded color sequence. With the prior art, using four colors allows only four different targets to be detected. By using only a 2-bit barcode, the disclosed method can detect 16 targets simultaneously.
[0011] As disclosed herein, target molecule analysis can be performed using OligoCASSEQ technology comprising an oligonucleotide tag (e.g., oligopaint). The read molecule can be used non-enzymatically to detect the identity of a specific oligonucleotide tag (e.g., oligopaint).
[0012] In one embodiment, a method for analyzing at least one target molecule in a sample is described herein, the method comprising: (a) contacting the sample with at least one oligonucleotide tag, wherein each oligonucleotide tag comprises (i) a recognition domain that specifically binds to the target molecule to be analyzed, and (ii) at least one street comprising at least one cassette, and each cassette comprises (1) a barcode region comprising at least one nucleotide having an anchor region flanked on at least one side; wherein the street of each oligonucleotide tag is at least unique from the street of another oligonucleotide tag in step (a) in that A. the spatial order of the cassettes within the street is different or B. the sequence of the barcode region is different from the barcode region of another oligonucleotide tag in step (a); (b) contacting the sample with at least two read molecules, wherein each read molecule comprises (i) an oligonucleotide that specifically hybridizes with the cassette of at least one oligonucleotide tag used in step (a); and (ii) a detection molecule, wherein the at least two read molecules collectively comprise at least two distinguishable detection molecules; and (c) a step of detecting the relative spatial order of the detection molecules hybridized to at least one oligonucleotide tag, wherein the at least one oligonucleotide tag is hybridized to the at least one target molecule, and thereby the relative spatial order of the detection molecules enables identification of which oligonucleotide tag is hybridized to the target molecule at a corresponding location.
[0013] In some embodiments of any aspect, the barcode region contains 1 to 10 nucleotides.
[0014] In some embodiments of any aspect, the street includes at least three cassettes.
[0015] In some embodiments of any mode, the barcode area is adjacent to each side by an anchor area.
[0016] In some embodiments of any mode, the anchor region of all oligonucleotide tags is constant.
[0017] In some embodiments of any mode, the specific hybridization of the read molecule for the cassette is determined by the identity of the barcode area.
[0018] In some embodiments of any mode, the detection molecule is a fluorescent molecule.
[0019] In some embodiments of any mode, detection is performed with a fluorescence microscope.
[0020] In some embodiments of any aspect, the detection molecule comprises biotin, amine, metal, anchor molecule, or acrideite.
[0021] In some embodiments of any modality, detection is performed at least with single-cell resolution.
[0022] In some embodiments of any mode, step (b) includes the step of contacting the sample with at least four read molecules.
[0023] In some embodiments of any mode, step (b) includes the step of contacting a sample with a group of read molecules collectively comprising at least three distinguishable detection molecules.
[0024] In some embodiments of any aspect, step (b) includes the step of contacting a sample with a group of read molecules collectively comprising at least four distinguishable detection molecules.
[0025] In some embodiments of any mode, at least two target molecules are analyzed simultaneously.
[0026] In some embodiments of any mode, at least three target molecules are analyzed simultaneously.
[0027] In some embodiments of any mode, at least 10 target molecules are analyzed simultaneously.
[0028] In some embodiments of any mode, at least 20 target molecules are analyzed simultaneously.
[0029] In some embodiments of any aspect, the target molecule is a nucleic acid, polypeptide, cell surface molecule, or inorganic material.
[0030] In some embodiments of any aspect, the target molecule is DNA or mRNA. In some embodiments of any aspect, the sample is a cell, cell culture, or tissue sample.
[0031] Another aspect described herein is a system for analyzing at least one target molecule in a sample, the system comprising: (a) a detector capable of detecting at least two detectable molecules; (b) at least one oligonucleotide tag, wherein each oligonucleotide tag comprises (i) a recognition domain that specifically binds to the target molecule to be analyzed; and (ii) a street comprising at least one cassette, wherein each cassette comprises a street comprising (1) a barcode region comprising at least one nucleotide, wherein an anchor region is adjacent to at least one side; wherein the street of each oligonucleotide tag is distinguished from the street of another oligonucleotide tag of (b) in that A. the spatial order of the cassettes within the street is different or B. the sequence of the barcode region is different from the barcode region of another oligonucleotide tag of (b); and (c) at least two read molecules, wherein each read molecule comprises (i) an oligonucleotide that specifically hybridizes with the cassette of at least one oligonucleotide tag used in (b); and (ii) a detection molecule; wherein the at least two reading molecules collectively comprise at least two distinguishable detection molecules; and the sample is in contact with the at least one oligonucleotide tag and the at least two reading molecules, and the relative spatial order of the detection molecules hybridized to the at least one oligonucleotide tag is detected, wherein the at least one oligonucleotide tag is hybridized to at least one target molecule, thereby allowing identification of which oligonucleotide tag is hybridized to the target molecule at the corresponding location. Brief explanation of the drawing
[0032] Figs. 1a–1hThis is a series of images and schematics showing genome tracing multiplexed with OligoCASSEQ. Fig. 1a This is a schematic diagram showing a modified oligopaint for OligoCASSEQ. Genome homology regions are hybridized to genomic DNA, and non-genome homology regions, MainStreet and BackStreet, are adjacent to the sides. The streets contain universal priming regions that allow for the amplification of the oligopaint library. The streets also contain sequencing cassettes (e.g., Cassette 1, Cassette 2, Cassette 3, Cassette 4) used for multiplexing. Although four cassettes are shown in this diagram, there is no limit to the total number of cassettes. Fig. 1b Figure 1a is a schematic diagram showing the sequencing cassette. The barcode area includes a variable area (X). Each bit (X) can be coded as one of four nucleotides (e.g., A, C, T, or G). Although a 5-nucleotide (nt) barcode is shown in this figure, the barcode length may vary. Increasing the barcode length increases multiplexing. The barcode is checked by a specific read oligo (e.g., see Figure 1c). Each probe contains a different barcode that enables multiplexing. On each side of the barcode area, there is a constant anchor area between all probes (e.g., 5nt is shown in this figure, but the barcode area length may vary). The anchor area provides stable hybridization and allows the barcodes to be distinguished. Fig. 1cFigure [Figure] is a schematic diagram showing exemplary read oligos for two locations within a cassette. Each pool of read oligos is used to scan a specific barcode location. Fluorescently labeled read oligo base pairs, specifically bound to the unique bases (e.g., A, C, G, and T) at a specific location, contain a nucleotide mixture of non-irradiated bases ("N"). The anchor ("Anch") nucleotide sequence is cassette-specific (e.g., Cassette 1 shares a specific anchor, and Cassette 2 shares a different anchor). Fig. 1d This is a schematic diagram illustrating an exemplary OligoCASSEQ experimental workflow for reading cassette positions 1 and 2. From left to right, the oligopaint probes are first hybridized to genomic DNA. A specific pool of read oligos is hybridized to barcode position 1 on cassette 1 ("A" of the cassette) and sequenced. The red "T" read oligos bind in complete complementarity with the cassette. After hybridization, an image is taken, and the read oligos are washed with 60% formamide in 2XSSCT. Then, the cassette 1 oligos are hybridized to position 2 to examine position 2 of cassette 1. Other positions and cassettes are examined in the same manner. Fig. 1e-Fig. 1h This is a series of images showing the localization of OligoCASSEQ at five loci along human chromosome 2 (Chr.2). Fig. 1e is a schematic diagram showing the Chr. 2 locus, nucleotide barcode, and color barcode used in the validation experiment (e.g., Fig. 1f-Fig. 1h reference). Fig. 1fThis image shows micrographs of OligoCASSEQ scans for two barcode locations (e.g., see top and middle sections), followed by a re-scan of the -1st location in the same nucleus (e.g., see bottom section). The schematic above each micrograph indicates the color code of a specific location at different barcode locations. Note that when both red and cyan-labeled probes are used, the red and cyan colors overlap due to a suboptimal set of microscope filters. However, when red and cyan overlap, the cyan is brighter than the red. The micrographs are maximum intensity z-projections from multiple z-slices. The cells are PGP1-F cells. Figure 1g is an image showing barcode identification. After sequencing for at least two locations, the OligoCASSEQ focus can be decoded. Fig. 1h This image demonstrates that OligoCASSEQ enables chromosome tracing, as it can identify genomic locations of all foci. The lines are 2D traces based on the decoded foci. The arrowheads indicate the bottom of the chromosome (e.g., the locus closest to the telomere of the long (q) arm). OligoCASSEQ can also be used in super-resolution microscopy using a read probe containing a compatible fluorescent dye (e.g., see Fig. 1c). Specific details for implementing the invention
[0033] Embodiments of the technology described herein include a method for analyzing target molecules using OligoCASSEQ. As described herein, OligoCASSEQ refers to a method, system, and / or composition comprising an oligonucleotide tag (e.g., oligopaint). The disclosed method allows for the simultaneous visualization of at least two targets or at least two regions of a single target. Additionally, through the use of a barcoded cassette, the disclosed method can visualize four or more targets simultaneously, which is more than can currently be detected with conventional oligopaints.
[0034] These methods are superior to alternative methods. The disclosed methods do not require enzymes, such as ligases or polymerases, which are required by alternative methods. The disclosed methods also involve shorter oligos and fewer oligos than are required by alternative techniques. Finally, the disclosed methods are simpler and cheaper than alternatives.
[0035] Accordingly, in one embodiment, a method for analyzing one or more target molecules in a sample is provided, the method comprising: (a) contacting the sample with at least one oligonucleotide tag (e.g., oligopaint), wherein each oligonucleotide tag comprises (i) a recognition domain that specifically binds to the target molecule to be analyzed, and (ii) at least one street comprising at least one cassette, and each cassette comprises (1) a barcode region comprising at least one nucleotide having an anchor region adjacent to at least one side; wherein the street of each oligonucleotide tag is distinguished from the street of another oligonucleotide tag in step (a) in that A. the spatial order of the cassettes within the street is different or B. the sequence of the barcode region is different from the barcode region of another oligonucleotide tag in step (a); (b) contacting the sample with at least two read molecules, wherein each read molecule comprises (i) an oligonucleotide that specifically hybridizes with the cassette of at least one oligonucleotide tag used in step (a); and (ii) comprising a detection molecule; wherein the at least two read molecules collectively comprise at least two distinguishable detection molecules; and (c) detecting the relative spatial order of the detection molecules hybridized to at least one oligonucleotide tag, wherein the at least one oligonucleotide tag is hybridized to the at least one target molecule, and thereby the relative spatial order of the detection molecules enables identification of which oligonucleotide tag is hybridized to the target molecule at a corresponding location.
[0036] In other words, the OligoCASSEQ method may include the steps of contacting a sample with an oligonucleotide tag (e.g., oligopaint), contacting the sample with at least two read molecules, and determining the spatial order of the barcoded cassette.
[0037] Another aspect described herein is a system for analyzing at least one target molecule in a sample, the system comprising: (a) a detector capable of detecting at least two detectable molecules; (b) at least one oligonucleotide tag (e.g., oligopaint), wherein each oligonucleotide tag comprises (i) a recognition domain that specifically binds to the target molecule to be analyzed, and (ii) a street comprising at least one cassette, and each cassette comprises (1) a barcode region comprising at least one nucleotide having an anchor region adjacent to at least one side; wherein the street of each oligonucleotide tag is distinguished from the street of another oligonucleotide tag in (b) in that A. the spatial order of the cassette within the street is different or B. the sequence of the barcode region is different from the barcode region of another oligonucleotide tag in (b); and (c) at least two read molecules, wherein each read molecule comprises (i) an oligonucleotide that specifically hybridizes with the cassette of at least one oligonucleotide tag used in (b); and (ii) a detection molecule; wherein the at least two reading molecules collectively comprise at least two distinguishable detection molecules. In some embodiments of any aspect, a sample is in contact with at least one oligonucleotide tag and at least two reading molecules, and the relative spatial order of the detection molecules hybridized to at least one oligonucleotide tag is detected (e.g., by a detector), wherein at least one oligonucleotide tag is hybridized to at least one target molecule, and thus the relative spatial order of the detection molecules allows identification of which oligonucleotide tag is hybridized to the target molecule at that location. In some embodiments of any aspect, the detection data is output on a display.
[0038] As used herein, the term “oligonucleotide tag” is an oligonucleotide comprising a recognition domain and / or at least one street. In some embodiments of any aspect, the oligonucleotide tag comprises, but is not limited to, any oligonucleotide and / or target molecule used in FISH methods, such as an oligopaint, a multiplexed error-robust fluorescence in situ hybridization (MERFISH) oligo, a seqFISH oligo, a target RNA sequential probing (SPOT) oligo, a high-range microscopy-based technique (Hi-M) oligo, or an optical reconstruction of chromatin structure (ORCA) oligo, or any oligonucleotide and / or target molecule, e.g., an oligonucleotide having an oligonucleotide sequence, a portion of a DNA sequence, or a sequence (e.g., a recognition domain) complementary to a specific chromosome or a subchromosomal region of a specific chromosome. For further details, refer to the following literature, each incorporated herein by reference in its entirety: Cardozo et al., Mol Cell. 2019 Apr 4;74(1):212-222; Mateo et al., Nature. 2019 Apr;568(7750):49-54; Wang et al., Scientific Reports volume 8, Article number: 4847 (2018); Shah et al., Neuron, Volume 92, Issue 2, 19 October 2016, Pages 342-357; Eng et al., Nat Methods. 2017 Dec;14(12):1153-1155.
[0039] As used herein, the term “street” refers to a portion of an oligonucleotide tag (e.g., oligopaint) that is not identical to the target sequence or does not hybridize to the target sequence. As used herein, the term “cassette” refers to a region of the street comprising a barcode region and at least one anchor region. As used herein, the term “barcode region” refers to a region of the cassette comprising at least one nucleotide. As used herein, the term “anchor region” refers to a region of the cassette that is specific to the set of cassettes and / or constant and / or complementary to the anchor-hybridization region of at least one read molecule. As used herein, the term “readout molecule” refers to a molecule comprising 1) a detection molecule or moiety and 2) an oligonucleotide sequence that is complementary to at least a portion of at least one cassette of at least one oligonucleotide tag (e.g., oligopaint) and / or specifically hybridizes to at least a portion of at least one cassette of at least one oligonucleotide tag (e.g., oligopaint).
[0040] In some embodiments of any aspect, an oligonucleotide tag (e.g., oligopaint) comprises at least one street, and said street comprises at least one cassette. As used herein, “cassette” refers to an area of the street comprising a barcode area and at least one anchor area. As a non-limiting example, the street comprises one cassette, two cassettes, three cassettes, four cassettes, five cassettes, six cassettes, seven cassettes, eight cassettes, nine cassettes, or at least ten cassettes.
[0041] In some embodiments of any aspect, an oligonucleotide tag (e.g., oligopaint) comprises at least one cassette, and a group of oligonucleotide tags comprises a subgroup of oligonucleotide tags, each subgroup being defined by the type of cassette(s) present in the oligonucleotide tag. Each cassette type comprises at least one distinct and / or distinguishable anchor region (i.e., the anchor region may be cassette type-specific), and each individual cassette comprises a distinct and / or distinguishable barcode region. As a non-limiting example, a group of oligonucleotide tags (e.g., oligopaint) comprises a type 1 cassette and a type 2 cassette, wherein a set of type 1 cassettes shares at least one anchor region different from the anchor region(s) shared by a set of type 2 cassettes. As a non-limiting example, a type 1 cassette comprises anchor region A and anchor region B, and a type 2 cassette comprises anchor region C and anchor region D. In some embodiments of any modality, cassette subgroups may share an anchor region, provided that at least one anchor region is separated from and / or distinguishable to each cassette subgroup. As a non-limiting example, a Type 1 cassette includes anchor region A and anchor region B, and a Type 2 cassette includes anchor region A and anchor region C.
[0042] In some embodiments of any aspect, the oligonucleotide tag (e.g., oligopaint) comprises a plurality of cassettes, each of which is of a different type (e.g., oligonucleotide tag X comprises a type 1 cassette, a type 2 cassette, and a type 3 cassette). In some embodiments of any aspect, the oligonucleotide tag (e.g., oligopaint) comprises a plurality of cassettes, wherein at least two cassettes are of the same type (e.g., oligonucleotide tag Y comprises two type 1 cassettes and one type 2 cassette). The presence of multiple copies of the same cassette type in the oligonucleotide tag (e.g., oligopaint) can be used to amplify a signal (e.g., mobilize two read molecules in the oligonucleotide tag). In some embodiments of any aspect, an oligonucleotide tag (e.g., oligopaint) or a group of oligonucleotide tags comprises one type of cassette, two types of cassettes, three types of cassettes, four types of cassettes, five types of cassettes, six types of cassettes, seven types of cassettes, eight types of cassettes, nine types of cassettes, or at least ten types of cassettes. In some embodiments of any aspect, each type of cassette may code for a specific identifier (e.g., chromosome number, chromosome arm, chromosome region, gene, etc.).
[0043] In some embodiments of any aspect, each oligonucleotide tag (e.g., oligopaint) within an oligonucleotide tag set has a distinct arrangement of cassettes, for example, the sequences of the cassettes may be distinct, but the cassettes in each different oligonucleotide tag are arranged in a different spatial order within a street. Thus, in some embodiments of any aspect, each oligonucleotide tag (e.g., oligopaint) within an oligonucleotide tag set has a street that is distinct, for example, in that the spatial order of the cassettes in the street of each oligonucleotide tag is different. In some embodiments of any aspect, each oligonucleotide tag (e.g., oligopaint) within an oligonucleotide tag set has a distinct cassette or set of cassettes. In some embodiments of any aspect, all cassettes in a street are identical to each other. In some embodiments of any aspect, all cassettes within an oligonucleotide tag (e.g., oligopaint) are identical to each other. In some embodiments of any aspect, at least one cassette is different from other cassettes within the same street or oligonucleotide tag (e.g., oligopaint). In some embodiments of any aspect, each and all cassettes are different from other cassettes within the same street or oligonucleotide tag (e.g., oligopaint). In some embodiments of any aspect, the main street comprises a cassette or set of cassettes, and the back street comprises a different cassette or set of cassettes. In some embodiments of any aspect, the main street and the back street share the same cassette or set of cassettes. In some embodiments of any aspect, each oligonucleotide tag (e.g., oligopaint) within the set of oligonucleotide tags shares the same cassette or set of cassettes, wherein the oligonucleotide tags hybridize to different target molecules within the set of oligonucleotide tags.
[0044] In some embodiments of any aspect, the cassette includes a barcode region. As used herein, the “barcode region” refers to a region of the cassette containing at least one nucleotide. As a non-limiting example, the barcode region includes one nucleotide, two nucleotides, three nucleotides, four nucleotides, five nucleotides, six nucleotides, seven nucleotides, eight nucleotides, nine nucleotides, or ten nucleotides. In some embodiments of any aspect, at least one nucleotide of the barcode region includes a modified nucleobase as further described herein.
[0045] In some embodiments of any aspect, the sequence of the barcode region is different from the barcode region of another oligonucleotide tag (e.g., oligopaint). In some embodiments of any aspect, each and all cassettes have a different barcode region, for example, a barcode region having a different sequence of nucleotides. In some embodiments of any aspect, each and all cassettes in the street have a barcode region different from other cassettes in the street, for example, a barcode region having a different sequence of nucleotides. In some embodiments of any aspect, the sequence of the barcode region is identical and is shared with at least one barcode region of another oligonucleotide tag (e.g., oligopaint). In some embodiments of any aspect, the barcode region is adjacent to at least one side by an anchor region. In some embodiments of any aspect, the barcode region is adjacent to both sides by an anchor region.
[0046] In some embodiments of any aspect, the cassette comprises at least one anchor region. As used herein, the “anchor region” refers to a region of the cassette that is specific to the cassette set and / or constant and / or complementary to the anchor-hybridization region of at least one read molecule. In some embodiments of any aspect, each cassette comprises at least one anchor region that is distinct from at least one anchor region of all other cassettes. As a non-limiting example, the anchor region comprises at least one nucleotide. As a non-limiting example, the anchor region comprises one nucleotide, two nucleotides, three nucleotides, four nucleotides, five nucleotides, six nucleotides, seven nucleotides, eight nucleotides, nine nucleotides, or ten nucleotides. In some embodiments of any aspect, the anchor region comprises at least five nucleotides.
[0047] In some embodiments of any aspect, an anchor region comprising five or fewer nucleotides (e.g., 1, 2, 3, 4, or 5 nucleotides) enables transient binding to an oligonucleotide tag (e.g., oligopaint) of a read molecule. As used herein, the term “transient binding” refers to a weak, reversible, and / or transient, specific interaction between molecules, i.e., a read molecule having a binding affinity that allows for repeated binding and unbinding. Such binding affinity can be measured using a dissociation constant Kd. In some embodiments of any aspect, transient binding may be defined as having a Kd in the μM range. In some embodiments of any aspect, an anchor region having low binding affinity for a target molecule may be used in a method in which transient binding to a target molecule is desired (e.g., DNA-exchange PAINT, e.g., see the following literature, each incorporated herein by reference in its entirety: US 2016 / 0161472 A1, Jungmann et al., Nano Lett. 2010, 10, 11, 4756-4761).
[0048] Non-limiting examples of anchor regions include the following: GTCTC( Sequence Number: 1 ); CACTA( Sequence No.: 2 ); GCCCG( Sequence Number: 3 ); and TGTGC( Sequence Number: 4 ).
[0049] As a non-limiting example, the cassette includes one anchor area or two anchor areas. In some embodiments of any aspect, the anchor area is 5' with respect to the barcode area and / or the anchor area is 3' with respect to the barcode area. In some embodiments of any aspect, the barcode area is adjacent to each side by the anchor area, for example, one anchor area is 5' with respect to the barcode area and one anchor area is 3' with respect to the barcode area.
[0050] Any individual cassette may optionally include additional sequences, e.g., linker or spacer sequences, to position it at a desired distance from other cassettes or elements of oligonucleotide tags (e.g., oligopaint).
[0051] In some embodiments of any aspect, each oligonucleotide tag (e.g., oligopaint) street is distinguished from other oligonucleotide tag streets by a cassette or set of cassettes. In some embodiments of any aspect, each oligonucleotide tag (e.g., oligopaint) street is distinguished from other oligonucleotide tag streets in that the spatial order of the cassettes within the street is different. As a non-limiting example, a street containing three cassettes (e.g., cassettes "A", "B", and "C") in spatial order 5'-ABC-3' has cassettes of a different spatial order compared to any other street containing cassettes of a spatial order selected from 5'-ACB-3', 5'-BAC-3', 5'-BCA-3', 5'-CAB-3', or 5'-CBA-3', and each of the aforementioned streets is distinguished from one another in the spatial order of these cassettes and is different from one another.
[0052] In some embodiments of any aspect, each street of oligonucleotide tags (e.g., oligopaint) is distinguished from other streets of oligonucleotide tags in that at least the barcode regions within the street are different. As a non-limiting example, for example, a street containing a barcode containing three nucleotides (e.g., nucleotides "X", "Y", and "Z") in the order 5'-XYZ-3' has a distinct barcode compared to other streets containing a barcode region selected from 5'-XZY-3', 5'-YXZ-3', 5'-YZX-3', 5'-ZXY-3', or 5'-ZYX-3', and each of the aforementioned streets is distinguished from one another in these barcode regions.
[0053] In some embodiments of any aspect, each street of oligonucleotide tags (e.g., oligopaint) is distinguished from other streets of oligonucleotide tags in that at least the spatial order of cassettes within the street is different, and each street of oligonucleotide tags is distinguished from other streets of oligonucleotide tags in that at least the barcode area or barcode areas within the street are different.
[0054] In some embodiments of any aspect, the method described herein comprises the step of contacting a sample with a readout molecule. As used herein, a “readout molecule” refers to a molecule comprising 1) a detection molecule or moiety and 2) an oligonucleotide sequence that is complementary to and / or specifically hybridizes to at least a portion of at least one cassette of at least one oligonucleotide tag (e.g., oligopaint). As a non-limiting example, the readout molecule comprises at least one region that is complementary to and specifically hybridizes to an anchor region of the cassette, e.g., an “anchor-hybridizing region.” As a non-limiting example, the readout molecule comprises at least one region that is complementary to and specifically hybridizes to a barcode region of the cassette, e.g., a “barcode-hybridizing region.” As a non-limiting example, the read molecule includes one anchor-hybridization region and / or two anchor-hybridization regions. In some embodiments of any embodiment, the anchor-hybridization region is 5' with respect to the barcode-hybridization region and / or the anchor-hybridization region is 3' with respect to the barcode-hybridization region. In some embodiments of any embodiment, the barcode-hybridization region is adjacent to each embodiment by the anchor-hybridization region, for example, one anchor-hybridization region is 5' with respect to the barcode-hybridization region and one anchor-hybridization region is 3' with respect to the barcode-hybridization region. In some embodiments of any embodiment, the anchor-hybridization region may be distinguished for the cassette type as described above for the anchor region distinguished for the cassette type.
[0055] In some embodiments of any aspect, the read molecule comprises a detection molecule, e.g., an optically detectable detection molecule. In some embodiments of any aspect, the detection molecule is a fluorophore, and detection is performed by a fluorescence microscope. In some embodiments of any aspect, the detection molecule comprises biotin, amine, metal, anchor molecule, or acrideite. Non-limiting examples of detection molecules, fluorophores, and detection techniques are further described herein.
[0056] In some embodiments of any aspect, at least two read molecules collectively comprise at least two distinguishable detection molecules. As a non-limiting example, two read molecules collectively comprise two distinguishable detection molecules, three read molecules collectively comprise three distinguishable detection molecules, four read molecules collectively comprise four distinguishable detection molecules, or at least five read molecules collectively comprise at least five distinguishable detection molecules. In some embodiments of any aspect, the pool of read molecules comprises more read molecules than distinguishable detection molecules, for example, the same detection molecule may exist on multiple read molecules.
[0057] In some embodiments of any aspect, the detection molecule may be connected to the 5' end of the read molecule, the detection molecule may be connected to the 3' end of the read molecule, or the detection molecule may be connected to both the 5' end and the 3' end of the read molecule. In some embodiments of any aspect, the detection molecule connected to the 5' end of the read molecule is the same type of detection molecule as the detection molecule connected to the 3' end of the read molecule. In some embodiments of any aspect, the detection molecule connected to the 5' end of the read molecule is a different type of detection molecule as the detection molecule connected to the 3' end of the read molecule.
[0058] In some embodiments of any aspect, the sample is in contact with at least two read molecules. In some embodiments of any aspect, the sample is in contact with at least one read molecule. As a non-limiting example, the sample is in contact with one read molecule, two read molecules, three read molecules, four read molecules, or at least five read molecules.
[0059] In some embodiments of any aspect, the method comprises the step of detecting a detection molecule of a read molecule hybridized to a detection molecule, for example, an oligonucleotide tag (e.g., oligopaint). In some embodiments of any aspect, the method comprises the step of detecting a detection molecule of a read molecule hybridized to a detection molecule, for example, an oligonucleotide tag (e.g., oligopaint) that is hybridized to one or more targets in turn.
[0060] In some embodiments of any aspect, the detection step includes detecting the relative spatial order of detection molecules hybridized to at least one oligonucleotide tag (e.g., oligopaint). Other markers (e.g., color) of the read molecules are correlated with one or more cassettes, and the spatial order of the other read molecules provides information about the order of the cassettes in a single oligonucleotide tag (e.g., oligopaint), so that a large number of different oligonucleotide tags are distinguished by a barcoded signal provided by a group of read molecules hybridized to a single street. Thus, in some embodiments of any aspect, the relative spatial order of the detection molecules allows identification of which oligonucleotide tag (e.g., oligopaint) is hybridized to the target molecule at that location.
[0061] In some embodiments of any aspect, the detection step includes detecting the relative spatial order of the detection molecules of the read molecules hybridized in at least one cassette, thereby allowing identification of which oligonucleotide tag (e.g., oligopaint) is hybridized to the target molecule at the corresponding location.
[0062] In some embodiments of any aspect, the detection step includes detecting the relative spatial order of read molecules hybridized in at least one cassette, thereby allowing identification of which oligonucleotide tag (e.g., oligopaint) hybridizes to the target molecule at the corresponding location.
[0063] In some embodiments of any aspect, the sample is in contact with a pool of read molecules, e.g., a “read pool.” In some embodiments of any aspect, the read pool comprises read molecules for the same cassette type (e.g., read molecules sharing at least one distinct anchor-hybridization region). In some embodiments of any aspect, the read pool comprises read molecules for at least one, at least two, at least three, at least four, or at least five cassette types.
[0064] In some embodiments of any aspect, each read pool relates to determining the identity of a nucleotide at a specific location within a barcode area of an oligonucleotide tag set (e.g., an oligopaint having a specific cassette type). As a non-limiting example, a sample is contacted sequentially or simultaneously with at least two read pools to detect at least one nucleotide in the barcode area. As a non-limiting example, a sample is contacted sequentially with at least two read pools to detect first and second cassette locations in one or more streets. In some embodiments of any aspect, the read pool comprises two read molecules, three read molecules, four read molecules, or at least five read molecules. In some embodiments of any aspect, the read pool comprises two distinct detection molecules, three distinct detection molecules, four distinct detection molecules, or at least five distinct detection molecules.
[0065] In some embodiments of any aspect, the read pool comprises a set of read molecules connected to a detection molecule of the same type. As a non-limiting example, the set of read molecules connected to a detection molecule of the same type comprises the same nucleotide at one location of the barcode-hybridization region and at least one of (1) a different nucleotide at another location of the barcode-hybridization region, (2) a degenerate set at another location of the barcode-hybridization region, or (3) a universal nucleotide at another location of the barcode-hybridization region. The universal nucleotide comprises a universal base capable of binding to any nucleotide. Non-limiting examples of universal bases include inosine, hypoxanthine, nitroazole, isocarbostyryl analogs, azole carboxamide, or aromatic triazole analogs (e.g., see the following literature: Loakes et al., Nucleic Acids Res. 2001 Jun 15;29(12):2437-47; Berger et al., Nucleic Acids Res. 2000 Aug 1; 28(15): 2911-2914; Liang et al., RSC Advances 3(35); June 2013).
[0066] In some embodiments of any aspect, the read pool comprises at least two sets of read molecules, wherein each set is connected to a detection molecule of the same type, which is distinguished from a detection molecule connected to another set(s) of read molecules, and each set detects the same nucleotide within a barcode area, which is distinguished from a nucleotide within the same location of the barcode area detected by the other set(s) of read molecules. In some embodiments of any aspect, the read pool comprises at least one set, two sets, three sets, four sets, or at least five sets of read molecules.
[0067] In some embodiments of any aspect, the sample is in contact with a first reading pool that recognizes the first nucleotide of the barcode area of each cassette (or recognizes another cassette at the first cassette location within the street). In some embodiments of any aspect, the sample is in contact with a second reading pool that recognizes the second nucleotide of the barcode area of each cassette (or recognizes another cassette at the second cassette location within the street). In some embodiments of any aspect, the sample is in contact with a third reading pool that recognizes the third nucleotide of the barcode area of each cassette (or recognizes another cassette at the third cassette location within the street). In some embodiments of any aspect, the sample is in contact with a fourth reading pool that recognizes the fourth nucleotide of the barcode area of each cassette (or recognizes another cassette at the fourth cassette location within the street). In some embodiments of any aspect, the sample is in contact with a 5th reading pool that recognizes the 5th nucleotide of the barcode area of each cassette (or recognizes another cassette at the 5th cassette location within the street). In some embodiments of any aspect, the sample is in contact with an nth reading pool that recognizes the nth nucleotide of the barcode area of each cassette (or recognizes another cassette at the nth cassette location within the street), where n is an integer between 1 and 10.
[0068] In some embodiments of any aspect, the sample is contacted sequentially with each reading pool. In some embodiments of any aspect, between contacting the sample with the nth reading pool and the (n+1)th reading pool, the reading pool is detected as described herein, and the nth reading pool is washed (e.g., any buffer suitable for use in a hybridization reaction, e.g., 60% formamide in 2XSSCT, where SSC refers to saline-sodium citrate buffer and T refers to TWEEN).
[0069] In some embodiments of any aspect, the sample is in contact with at least two read pools simultaneously. As a non-limiting example, the sample is in contact with at least two read pools, at least three read pools, at least four read pools, or at least five read pools simultaneously. Compared to contacting the sample with one read pool, contacting the sample with at least two read pools simultaneously may provide additional advantages, including but not limited to signal amplification, introduction of additional optically detectable markers (e.g., combinations of similar colors of different fluorescent dyes), and increased process speed.
[0070] In some embodiments of any aspect, a method for analyzing at least one target molecule in a sample comprises the steps of contacting the sample with at least one oligonucleotide tag (e.g., oligopaint), contacting the sample with at least two read molecules, and detecting the relative spatial order of the read molecules. In some embodiments of any aspect, the specific hybridization of the read molecules to the cassette is determined by or depends on the identity of the barcode region.
[0071] In some embodiments of any aspect, the compositions and methods described herein include improvements to the compositions and methods related to oligopaint technology. As used herein, the term “oligopaint” refers to a sequence complementary to a target molecule, for example, an oligonucleotide sequence, a portion of a DNA sequence, or a polynucleotide having a specific chromosome or a subchromosomal region of a specific chromosome.
[0072] Typically, fluorescence in situ hybridization (FISH) probes are derived from replicated genomic regions or flow-sorted chromosomes, which are directly labeled via nick translation or PCR in the presence of fluorescence-conjugated nucleotides or indirectly labeled with nucleotide-conjugated haptens, such as biotin and digoxigenin, and then visualized with a secondary detection reagent. Conventional FISH probes are limited by repetitive sequences and variable efficacy. Additionally, target regions are limited by the availability of clones and the size of genomic inserts. While it is possible to target larger regions using conventional FISH probes, this approach is often difficult and costly because each clone must be manufactured and optimized separately for hybridization.
[0073] Oligo-paints are an improved FISH technology, and oligo libraries can be generated by high-throughput parallel synthesis and used as a renewable source of probes. Oligo libraries can be PCR-amplified (optionally with fluorophore-conjugated primers). The amplification products can be enzymatically processed to generate high-efficiency single-strand, strand-specific probes capable of visualizing regions ranging from tens of kilobases to megabases. Oligo-paints may optionally include computationally patterned and / or computationally designed synthetic probes and arrays.
[0074] Publications regarding oligopaints and related technologies refer to, for example, the following literature, each incorporated herein by reference in its entirety: Beliveau et al. OligoMiner provides a rapid, flexible environment for the design of genome-scale oligonucleotide in situ hybridization probes. Proc. Nat. Acad. Sci. USA 2018 115:E2183-E2192; Beliveau et al. In situ super-resolution imaging of genomic DNA with OligoSTORM and OligoDNA-PAINT. Methods Mol Biol 2017 1663:231-252; Wang et al. Spatial organization of chromatin domains and compartments in single chromosomes. Science 2016 353:598-602; Boettiger et al. Super-resolution imaging reveals distinct chromatin folding for different epigenetic states. Nature. 2016 529:418-22; Schmidt et al. Scalable amplification of strand subsets from chip-synthesized oligonucleotide libraries. Nat Commun 2015 Nov 16;6:8634; Murgha et al. Combined in vitro transcription and reverse transcription method to amplify and label complex synthetic oligonucleotide probe libraries. Biotechniques 2015 58:301-7; Beliveau et al.Single-molecule super-resolution imaging of chromosomes and in situ haplotype visualization using Oligopaint FISH probes. Nat Commun 2015 6:7147; Beliveau et al. Visualizing genomes with Oligopaint FISH probes. Curr Protocols Mol Biol 2014 14.23; Beliveau et al. A versatile design and synthesis platform for visualizing genomes with Oligopaint FISH probes. Proc. Nat. Acad. Sci. USA 2012 109:21301-6; US 2010 / 0304994 A1; US 2018 / 0223347 A1; WO 2018 / 045186 A1; US 2014 / 0364333 A1; US 2019 / 0032121 A1; US 2013 / 0143208 A1; US 10,119,160 B2; US 2018 / 0057867 A1; US 2019 / 0127786 A1; US 2018 / 0292318 A1; WO 2017 / 189525 A1; WO 2018 / 183851 A1; WO 2018 / 183860 A1; WO 2018 / 045181 A1; US 2016 / 0040235 A1.
[0075] As used herein, the terms “oligopainted” and “oligopainted region” each refer to a target nucleotide sequence (e.g., chromosome) or a region of a target nucleotide sequence (e.g., subchromosome region) hybridized with one or more oligopaints. Oligopaints may be used to label the target nucleotide sequence, chromosomes, and subchromosome regions of chromosomes during various stages of the cell cycle, including but not limited to interphase, preprophase, prophase, prometaphase, metaphase, anaphase, telophase, and cytokinesis.
[0076] In some embodiments of any aspect, the FISH method may include any method comprising the step of contacting a sample with an oligopaint, multiplexing error-robust fluorescence in situ hybridization (MERFISH), seqFISH, sequential RNA probing of a target (SPOT), high-range microscopy-based techniques (Hi-M), or optical reconstruction of chromatin structure (ORCA), or a target molecule, e.g., an oligonucleotide sequence, a portion of a DNA sequence, or an oligonucleotide having a sequence (e.g., a recognition domain) complementary to a specific chromosome or a sub-chromosomal region of a specific chromosome. For further details, refer to the following literature, each incorporated herein by reference in its entirety: Cardozo et al., Mol Cell. 2019 Apr 4;74(1):212-222; Mateo et al., Nature. 2019 Apr;568(7750):49-54; Wang et al., Scientific Reports volume 8, Article number: 4847 (2018); Shah et al., Neuron, Volume 92, Issue 2, 19 October 2016, Pages 342-357; Eng et al., Nat Methods. 2017 Dec;14(12):1153-1155.
[0077] In some embodiments of any aspect, the method described herein comprises the step of analyzing at least one target molecule in a sample. In some embodiments of any aspect, the target molecule comprises nucleic acids, polypeptides, cell surface molecules, and / or inorganic materials. In some embodiments of any aspect, the target molecule comprises DNA, including but not limited to genomic DNA, genomic DNA organized as a chromosome, or complementary DNA (cDNA). In some embodiments of any aspect, the target molecule comprises RNA, including but not limited to messenger RNA (mRNA) or ribosomal RNA (rRNA). In some embodiments of any aspect, the target molecule comprises polypeptides, including but not limited to intracellular proteins, transmembrane proteins, or extracellular proteins. In some embodiments of any aspect, the target molecule comprises cell surface molecules, including but not limited to transmembrane proteins, membrane lipids, membrane receptors, or transmembrane receptors. In some embodiments of any aspect, the target molecule comprises an inorganic material comprising any material derived from an inanimate source, including but not limited to glass, ceramic, metal, or any other solid substrate.
[0078] In some embodiments of any mode, one target molecule is analyzed. In some embodiments of any mode, at least two target molecules are analyzed simultaneously. As a non-limiting example, at least two target molecules, at least three target molecules, at least four target molecules, at least five target molecules, at least six target molecules, at least seven target molecules, at least eight target molecules, at least nine target molecules, at least ten target molecules, or at least twenty target molecules are analyzed simultaneously.
[0079] In some embodiments of any aspect, one or more regions of the target molecule are analyzed simultaneously. As a non-limiting example, two, three, four, five, six, seven, eight, nine, ten, or more regions of the target molecule are analyzed.
[0080] In some embodiments of any aspect, the sample is a cell, cell culture, or tissue sample. As a non-limiting example, the cell, cell culture, or tissue sample is taken at a time or under conditions where individual chromosomes can be distinguished, e.g., during mitosis.
[0081] As used herein, the terms “sample” or “test sample” refer to a sample taken or separated from a biological organism, e.g., a blood or tissue sample of a subject. In some embodiments of any aspect, the present invention comprises various examples of biological samples. In some embodiments of any aspect, a biological sample is, but not limited to, a cell, or a tissue, or peripheral blood, or a body fluid. Exemplary biological samples include biopsies, tumor samples, biofluid samples; blood; serum; plasma; urine; semen; mucus; tissue biopsies; organ biopsies; synovial fluid; bile; cerebrospinal fluid; mucosal secretions; effusions; sweat; saliva; and / or tissue samples, etc. The term also includes mixtures of the aforementioned samples. The term “test sample” also includes untreated or pre-treated (or pre-processed) biological samples. In some embodiments of any aspect, a test sample comprises cells from a subject.
[0082] Test samples may be obtained by extracting a sample from the subject, but they may also be obtained using previously isolated samples (e.g., those isolated at a previous time and isolated by the same person or another person).
[0083] In some embodiments of any aspect, the test sample may be an untreated test sample. The phrase “untreated test sample,” as used herein, refers to a test sample that has not undergone any prior sample pretreatment, except dilution and / or suspension in a solution. Exemplary methods for treating the test sample include, but are not limited to, centrifugation, filtration, sonication, homogenization, heating, freezing and thawing, and combinations thereof. In some embodiments of any aspect, the test sample may be a frozen test sample, for example, frozen tissue. The frozen sample may be thawed before using the methods, analyses, and systems described herein. After thawing, the frozen sample may be centrifuged before being applied to the methods, analyses, and systems described herein. In some embodiments of any aspect, the test sample is a purified test sample, for example, by centrifugation and collection of the supernatant containing the purified test sample. In some embodiments of any aspect, the test sample may be a supernatant or filtrate produced from a pre-processed test sample, for example, from a treatment selected from the group consisting of centrifugation, filtration, thawing, purification, and any combination thereof. In some embodiments of any aspect, the test sample may be treated with chemical and / or biological reagents. Chemical and / or biological reagents may be used to protect and / or maintain the stability of a sample containing biomolecules (e.g., nucleic acids and proteins) during processing. One exemplary reagent is a protease inhibitor commonly used to protect or maintain the stability of proteins during processing. Those skilled in the art are well aware of appropriate methods and processes for the pre-processing of biological samples necessary to determine the levels of expression products as described herein.
[0084] In some embodiments of any aspect, the method, test, and system described herein may further include the step of obtaining or obtaining a test sample from an object. In some embodiments of any aspect, the object may be a human object.
[0085] In some embodiments of any aspect, an oligonucleotide tag (e.g., oligopaint) comprises a recognition domain. As used herein, the "recognition domain" is a domain of an oligonucleotide tag (e.g., oligopaint) that specifically binds to a target molecule and / or sequence to be analyzed. As a non-limiting example, the recognition domain may be a nucleic acid sequence complementary to a region of a chromosome, e.g., a target molecule and / or sequence. Thus, the sequence of the recognition domain will vary depending on the identity of the desired target. For example, it is within the scope of the art to design a recognition domain that specifically hybridizes to any given target under specific conditions using software that is widely and freely available for this purpose (e.g., Primer3 or PrimerBank, both of which are available on the World Wide Web). In some embodiments of any aspect, the recognition domain may have at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity with a portion of the target molecule and / or target sequence. In some embodiments of any aspect, the recognition domain includes a domain of "genomic homology" or a domain that specifically binds to a region of the genome. In some embodiments of any aspect, multiple recognition domains found in the same or different oligonucleotide tags (e.g., oligopaints) may specifically bind to a single target molecule and / or target sequence.As a non-limiting example, at least 2 recognition domains, at least 3 recognition domains, at least 4 recognition domains, at least 5 recognition domains, at least 10 recognition domains, at least 20 recognition domains, at least 30 recognition domains, at least 40 recognition domains, or at least 50 recognition domains may specifically bind to a target molecule and / or a target sequence.
[0086] In some embodiments of any aspect, the recognition domain comprises, but is not limited to, any oligonucleotide and / or target molecule used in FISH methods, such as an oligopaint, a multiplexing error-robust fluorescence in situ hybridization (MERFISH) oligo, a seqFISH oligo, a target RNA sequential probing (SPOT) oligo, a high-range microscopy-based technique (Hi-M) oligo, or an optical reconstruction of chromatin structure (ORCA) oligo, or any oligonucleotide and / or target molecule used in FISH methods, e.g., an oligonucleotide sequence, a portion of a DNA sequence, or any oligonucleotide having a sequence (e.g., a recognition domain) complementary to a specific chromosome or a sub-chromosomal region of a specific chromosome. For further details, refer to the following literature, each incorporated herein by reference in its entirety: Cardozo et al., Mol Cell. 2019 Apr 4;74(1):212-222; Mateo et al., Nature. 2019 Apr;568(7750):49-54; Wang et al., Scientific Reports volume 8, Article number: 4847 (2018); Shah et al., Neuron, Volume 92, Issue 2, 19 October 2016, Pages 342-357; Eng et al., Nat Methods. 2017 Dec;14(12):1153-1155.
[0087] In some embodiments of any aspect, the recognition domain comprises any nucleic acid-binding composition, such as a non-nucleic acid, e.g., a DNA-binding polypeptide. As a non-limiting example, the recognition domain comprises a sequence-specific single-stranded DNA-binding protein or factor, a sequence-specific double-stranded DNA-binding protein or factor, a DNA-RNA-binding protein or factor, or an RNA-binding protein or factor. Non-limiting examples of such nucleic acid-binding compositions include, but are not limited to, transcription factors, restriction enzymes, transcription activator-like effector nucleases (TALENs), CRISPR-Cas-type factors, etc. In some embodiments of any aspect, the nucleic acid-binding composition lacks nuclease activity.
[0088] In some embodiments of any aspect, the target molecule comprises a non-nucleic acid, e.g., a polypeptide. Accordingly, the recognition domain comprises any composition that specifically binds to the target polypeptide. Non-limiting examples of such polypeptide-binding recognition domains include, but are not limited to, antibodies (e.g., nanobodies), aptamers, small molecules, ligands, known binding partners of a specific polypeptide, etc.
[0089] In some embodiments of any aspect, the oligonucleotide tag does not specifically recognize a target molecule in that the oligonucleotide tag is not connected to a recognition domain but is connected to an entity for detecting the oligonucleotide-tagged entity of interest. The oligonucleotide tag may be a nucleic acid lacking a recognition domain, for example, and may include at least one anchor region and at least one barcode region. As a non-limiting example, such an oligonucleotide-tagged entity may include a small molecule (e.g., for drug screening purposes), a polypeptide, a cell, or a non-biological substance (e.g., a metal, a chemical, etc.). A method for detecting such an oligonucleotide-tagged entity may be the same as that used to detect an oligonucleotide tag (e.g., an oligopaint) as described herein (e.g., by contacting a pool of read molecules hybridizing to a specific cassette type within the oligonucleotide tag). In some embodiments of any aspect, multiple types of target molecules and / or tagged entity types may be detected at once using, for example, at least one oligonucleotide tag that recognizes DNA (e.g., oligopaint), at least one oligonucleotide tag that recognizes polypeptides, and / or at least one oligonucleotide-tagged entity.
[0090] In some embodiments of any aspect, the oligonucleotide tag (e.g., oligopaint) comprises at least one street. As used herein, the term “street” refers to a portion of the oligonucleotide tag (e.g., oligopaint) that does not have identity with the target sequence or hybridize to the target sequence. The street comprises a detection region and / or an amplification region. As a non-limiting example, the oligonucleotide tag (e.g., oligopaint) comprises two streets. In some embodiments of any aspect, the street may be one or more of a “main street” and / or a “back street.” As a non-limiting example, the main street is 5’ for the recognition domain, the main street is 5’ for the back street, and / or the main street is 5’ for both the recognition domain and the back street. As a non-limiting example, the backstreet is 3' for the perception domain, the backstreet is 3' for the mainstreet, and / or the backstreet is 3' for both the perception domain and the mainstreet. As a non-limiting example, the mainstreet is 3' for the perception domain, the mainstreet is 3' for the backstreet, and / or the mainstreet is 3' for both the perception domain and the backstreet. As a non-limiting example, the backstreet is 5' for the perception domain, the backstreet is 5' for the mainstreet, and / or the backstreet is 5' for both the perception domain and the mainstreet.
[0091] In some embodiments of any aspect, the street (e.g., main street and / or back street) comprises at least one cassette and / or at least one universal priming region. As described herein, the cassette comprises at least one barcode region and at least one anchor region. As used herein, "universal priming region" means a region that binds to a universal primer (e.g., universal forward primer, universal reverse primer). As used herein, "universal primer" means a primer used for a plurality of individual oligonucleotide tags (e.g., oligopaint) or a set of oligonucleotide tags. Universal primers may be used, for example, for the purpose of amplifying oligonucleotide tags (e.g., oligopaint) by PCR for the generation of oligonucleotide tags or a set of oligonucleotide tags. In some embodiments of any aspect, the universal priming region of each oligonucleotide tag (e.g., oligopaint) is identical to the universal priming region of any other oligonucleotide tag to which the sample contacts.
[0092] In some embodiments of any aspect, the street comprises at least one universal priming region and / or at least one cassette. As a non-limiting example, the universal priming region is the 5' end of at least one cassette. As a non-limiting example, the universal forward priming region, which specifically binds to a universal forward primer, is located at the 5' end of an oligonucleotide tag (e.g., oligopaint). As a non-limiting example, the universal priming region is the 3' end of at least one cassette. As a non-limiting example, the universal reverse priming region, which specifically binds to a universal reverse primer, is located at the 3' end of an oligonucleotide tag (e.g., oligopaint). In some embodiments of any aspect, the universal priming region is adjacent to any aspect of the cassette (both 5' and 3') present in the oligonucleotide tag (e.g., oligopaint). In some embodiments of any aspect, the universal reverse priming region includes a recognition site for the nicking endonuclease (NE) to cause the oligonucleotide tag (e.g., oligopaint) to become single-stranded when exposed to the nicking endonuclease (NE), for example. In some embodiments of any aspect, the oligonucleotide tag (e.g., oligopaint) is not necessarily amplified (e.g., via PCR and / or the universal priming region). In some embodiments of any aspect, the described oligonucleotide tag (e.g., oligopaint) is newly ( de novo ), can be synthesized and can be used "straight from the tube".
[0093] In some embodiments of any aspect, detection is performed at least with a single-cell resolution. As a non-limiting example, detection may be performed with a resolution of at least 200 nm, at least 300 nm, at least 400 nm, at least 500 nm, at least 600 nm, at least 700 nm, at least 800 nm, at least 900 nm, at least 1 µm, at least 2 µm, at least 3 µm, at least 4 µm, at least 5 µm, at least 6 µm, at least 7 µm, at least 8 µm, at least 9 µm, or at least 10 µm. In some embodiments of any aspect, detection is performed with a resolution capable of distinguishing individual target molecules, e.g., chromosomes.
[0094] In some embodiments of any modality, nucleic acids, e.g., oligonucleotide tags (e.g., oligopaints), are chemically modified to enhance stability or other beneficial properties. The nucleic acids described herein are based on the literature incorporated herein by reference ["Current protocols in nucleic acid chemistry," Beaucage, SL et al. It may be synthesized and / or modified by methods well established in the art, such as those described in [(Edrs.), John Wiley & Sons, Inc., New York, NY, USA]. Modifications include backbone modifications, for example, (a) end modifications, e.g., 5' end modifications (phosphorylation, conjugation, reverse linkage, etc.), 3' end modifications (conjugation, DNA nucleotide, reverse linkage, etc.), (b) base modifications, e.g., replacement of a stabilizing base, an destabilizing base, or a base that forms base pairs with an extended repertoire of partners, removal of a base (abasic nucleotide), or conjugated base, (c) sugar modifications (e.g., 2' position or 4' position) or substitution of a sugar, as well as (d) modification or substitution of phosphodiester bonds. Specific examples of nucleic acid compounds useful in the embodiments described herein include, but are not limited to, nucleic acids containing a modified backbone or not containing natural nucleoside linkages. having a modified backbone Nucleic acids include, above all, those that do not have a phosphorus atom in their backbone. For the purposes of this specification, and as sometimes referred to in the art, a modified nucleic acid that does not have a phosphorus atom in its internucleoside backbone may also be considered an oligonucleoside. In some embodiments of any aspect, the modified nucleic acid will have a phosphorus atom in its internucleoside backbone.
[0095] Modified nucleic acid backbones may include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, 3'-aminophosphoamidates and aminoalkylphosphoamidates, phosphoamidates, thionoalkylphosphotriesters, and boranophosphates having a normal 3'-5' linkage, their 2'-5' linked analogs, and those having reverse polarity (wherein adjacent pairs of nucleoside units are linked from 3'-5' to 5'-3' or from 2'-5' to 5'-2'). Various salts, mixed salts, and free acid forms are also included. Modified nucleic acid backbones that do not contain internal phosphorus atoms have backbones formed by linkages between short-chain alkyl or cycloalkyl nucleosides, linkages between mixed heteroatoms and alkyl or cycloalkyl nucleosides, or linkages between one or more short-chain heteroatoms or heterocyclic nucleosides. These have morpholino linkages (partially formed from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide, and sulfone backbones; formacetyl and thioformacetyl backbones; methyleneformacetyl and thioformacetyl backbones; alkene-containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; It includes oligonucleosides having mixed N, O, S, and CH2 constituent parts and heteroatom backbones, in particular --CH2--NH--CH2--, --CH2--N(CH3)--O--CH2--[known as methylene (methylimino) or MMI backbone], --CH2--O--N(CH3)--CH2--, --CH2--N(CH3)--N(CH3)--CH2--, and --N(CH3)--CH2--CH2--[wherein the natural phosphodiester backbone is denoted as --O--P--O--CH2--].
[0096] The modified nucleic acid may also contain one or more substituted sugar moiety. The nucleic acid described herein may comprise one of the following at the 2' position: OH; F; O-, S- or N-alkyl; O-, S- or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C1 to C10 alkyl or C2 to C10 alkenyl and alkynyl. Exemplary suitable variations include O[(CH2)nO]mCH3, O(CH2)·nOCH3, O(CH2)nNH2, O(CH2)nCH3, O(CH2)nONH2, and O(CH2)nON[(CH2)nCH3)]2, wherein n and m are 1 to about 10. In some embodiments of any aspect, the dsRNA comprises one of the following at the 2' position: C1 to C10 lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH3, OCN, Cl, Br, CN, CF3, OCF3, SOCH3, SO2CH3, ONO2, NO2, N3, NH2, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, RNA cleavage group, reporter group, intercalator, group for improving the pharmacokinetic properties of the nucleic acid, or group for improving the pharmacodynamic properties of the nucleic acid, and other substituents having similar properties. In some embodiments of any aspect, the modification comprises 2' methoxyethoxy (also known as 2'-O--CH2CH2OCH3, 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., Helv. Chim. Acta, 1995, 78:486-504), i.e., an alkoxy-alkoxy group.Another exemplary variation includes 2'-dimethylaminooxyethoxy, i.e., the O(CH2)2ON(CH3)2 group also known as 2'-DMAOE as described in the examples of this specification below, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylaminoethoxyethyl or 2'-DMAOEE), i.e., 2'-O--CH2--O--CH2--N(CH2)2 as described in the examples of this specification below.
[0097] Other modifications include 2'-methoxy (2'-OCH3), 2'-aminopropoxy (2'-OCH2CH2CH2NH2), and 2'-fluoro (2'-F). Similar modifications may also occur at other locations on the nucleic acid, particularly at the 3' position of the sugar on the 3'-terminal nucleotide or at the 5' position of the 2'-5' linked dsRNA and the 5'-terminal nucleotide. The nucleic acid may also have sugar mimics, such as cyclobutyl moiety, instead of the pentopuranosyl sugar.
[0098] Nucleic acids may also include modifications or substitutions of nucleobases (simply referred to as "bases" in the art). As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C), and uracil (U). The modified nucleobases are 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothimine and 2-thiocytosine, 5-haloracil and cytosine, 5-propynyluracil and cytosine, 6-azouracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenine and guanine, 5-halo, particularly 5-bromo, 5-trifluoromethyl and others Synthetic and natural nucleobases may be included, but not limited to, 5-substituted uracil and cytosine, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azadenine, 7-deazaguanine and 7-dazadenine, and 3-deazaguanine and 3-dezadenine. Certain nucleobases among these are particularly useful for increasing the binding affinity of the inhibitory nucleic acid characterized in the present invention. These include 5-substituted pyrimidines, 6-azapyrimidines, and N-2, N-6, and O-6 substituted purines, and include 2-aminopropyladenine, 5-propynyluracil, and 5-propynylcytosine. 5-methylcytosine substitution was found to increase nucleic acid double helix stability by 0.6 to 1.2°C (Sanghvi, YS, Crooke, ST and Lebleu, B., Eds., dsRNA Research and Applications, CRC Press, Boca Raton, 1993, pp.276-278), this is an exemplary base substitution, even more particularly when combined with a 2'-O-methoxyethyl sugar modification. In some embodiments of any aspect, the modified nucleobase may include d5SICS and dNAM, which are non-limiting examples of non-natural nucleobases that can be used individually or together as base pairs (e.g., Leconte et al. J. Am. Chem. Soc. 2008, 130, 7, 2336-2343; Malyshev et al. PNAS. 2012. 109 (30) 12005-12010). In some embodiments of any aspect, the oligonucleotide tag (e.g., oligopaint) comprises any modified nucleobase known in the art, i.e., any nucleobase modified from an unmodified and / or natural nucleobase.
[0099] The preparation of the modified nucleic acids, backbones, and nucleobases described above is well known in the art.
[0100] Another modification of the nucleic acid characterized in the present invention includes chemically linking the nucleic acid to one or more ligands, moieties, or conjugates that enhance the activity, cell distribution, pharmacokinetic properties, or cell uptake of the nucleic acid. These moiety is, but is not limited to, lipid moiety, e.g., cholesterol moiety (Letsinger et al., Proc. Natl. Acid. Sci. USA, 1989, 86: 6553-6556), cholic acid (Manoharan et al., Biorg. Med. Chem. Let., 1994, 4:1053-1060), thioethers, e.g., beryl-S-tritylthiol (Manoharan et al., Ann. NY Acad. Sci., 1992, 660:306-309; Manoharan et al., Biorg. Med. Chem. Let., 1993, 3:2765-2770), thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20:533-538), Aliphatic chains, e.g., dodecanediol or undecyl residues (Saison-Behmoaras et al., EMBO J, 1991, 10:1111-1118; Kabanov et al., FEBS Lett., 1990, 259:327-330; Svinarchuk et al., 15 Biochimie:49-54), phospholipids, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36:3651-3654; Shea et al., Nucl. Acids Res., 1990, 18:3777-3783), polyamines or polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14:969) -973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett.Includes palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264:229-237), or octadecylamine or hexylamino-carbonyloxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277:923-937).
[0101] In some embodiments of any aspect, the measurement and / or detection of a target molecule, e.g., a DNA target molecule, an RNA target molecule, or a polypeptide target molecule, comprises the step of contacting a sample obtained from an object with a reagent or reagents such as those described herein. In some embodiments of any aspect, the reagent is labeled detectably. In some embodiments of any aspect, the reagent may generate a detectable signal. In some embodiments of any aspect, the reagent generates a detectable signal when the target molecule is present.
[0102] In some embodiments of any aspect, one or more of the reagents described herein may include a detectable label and / or may include an activity that generates a detectable signal (e.g., by a catalytic reaction that converts a compound into a detectable product). The detectable label may include, for example, a light-absorbing dye, a fluorescent dye, or a radioactive label. Detectable labels, methods for detecting them, and methods for incorporating them into the reagents described herein are well known in the art.
[0103] In some embodiments of any aspect, the detectable label, molecule, and / or moiety may comprise one that can be detected by spectroscopic, photochemical, biochemical, immunochemical, electromagnetic, radiochemical, or chemical means, such as fluorescence, chemiluminescence, or chemiluminescence, or other suitable means. The detectable label used in the method described herein may be a primary label (wherein the label comprises a moiety that is directly detectable or generates a directly detectable moiety) or a secondary label (wherein the detectable label binds to another moiety to generate a detectable signal, such as commonly seen in immunological labels using secondary and tertiary antibodies). The detectable label may be linked to a reagent by covalent or non-covalent means. Alternatively, the detectable label may be linked by directly labeling a molecule that achieves binding to the reagent through a ligand-receptor binding pair array or other such specific recognition molecules. Detectable labels may include, but are not limited to, radioactive isotopes, bioluminescent compounds, chromophores, antibodies, chemiluminescent compounds, fluorescent compounds, metal chelates, and enzymes.
[0104] In another embodiment, the detection reagent is labeled with a fluorescent compound. When the fluorescently labeled reagent is exposed to light of an appropriate wavelength, its presence can be detected due to fluorescence. In some embodiments of any aspect, the detectable label is a fluorescent dye molecule, or, but is not limited thereto, fluorescein, phycoerythrin, phycocyanin, o-phthalaldehyde, fluorescarmine, Cy3™, Cy5™, allophycocyanin, Texas Red, ferridinine chlorophyll, cyanin, phycoerythrin-Cy5™, green fluorescent protein, rhodamine, tandem conjugates such as fluorescein isothiocyanate (FITC) and Oregon Green™, rhodamine and derivatives (e.g., Texas Red and tetrarodimine isothiocyanate (TRITC)), biotin, AMCA, CyDyes™, , 6-carboxyfluorescein (commonly known by the abbreviations FAM and F), 6-carboxy-2',4',7',4,7-hexachlorofluorescein (HEX), 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein (JOE or J), N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA or T), 6-carboxy-X-rhodamine (ROX or R), 5-carboxyrhodamine-6G (R6G5) or G5), 6-carboxyrhodamine-6G (R6G6 or G6), and rhodamine 110; cyanine dyes, e.g., Cy3, Cy5, and Cy7 dyes; coumarins, e.g., umbelliferone; Fluorescent monochemicals may include benzimide dyes, e.g., Hoechst 33258; phenanthridine dyes, e.g., Texas Red; ethidium dyes; acridine dyes; carbazole dyes; phenoxazine dyes; porphyrin dyes; polymethine dyes, e.g., cyanine dyes such as Cy3, Cy5, etc.; BODIPY dyes and quinoline dyes. In some embodiments of any aspect, the detectable label may be, but is not limited thereto, 3 H, 125 I, 35 S,14 C, 32 P, and 33 It may be a radioactive label containing P. In some embodiments of any aspect, the detectable label may be an enzyme including horseradish peroxidase and alkaline phosphatase, but is not limited thereto. The enzyme label may, for example, produce a chemiluminescent signal, a color signal, or a fluorescent signal. Enzymes considered to be used to detectably label antibody reagents include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-V-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-VI-phosphate dehydrogenase, glucoamylase, and acetylcholinesterase. In some embodiments of any aspect, the detectable label is a chemiluminescent label comprising, but is not limited to, lucigenin, luminol, luciferin, isoluminol, temaric acridinium ester, imidazole, acridinium salt, and oxalate ester. In some embodiments of any aspect, the detectable label may be a spectral colorimetric label comprising, but is not limited to, colloidal gold or colored glass or plastic (e.g., polystyrene, polypropylene, and latex) beads.
[0105] In some embodiments of any aspect, the detection reagent may also be labeled with a detectable tag such as c-Myc, HA, VSV-G, HSV, FLAG, V5, HIS, or biotin. Other detection systems, for example, biotin-streptavidin systems may also be used. In this system, an antibody that is immunoreactive (i.e., specific) to the biomarker of interest is biotinized. The amount of biotinized antibody bound to the biomarker is determined using a streptavidin-peroxidase conjugate and a chromogenic substrate. Such streptavidin peroxidase detection kits are commercially available, for example, from DAKO (Carpinteria, CA). The reagent also 152 It can be detectably labeled using fluorescently emitting metals such as Eu or other metals of the lanthanide series. These metals can be attached to reagents using metal chelate groups such as diethylenetriaminepentaacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA).
[0106] The detection method(s) used may vary depending on the specific detectable label used on the read molecule. In certain exemplary embodiments, chromosomes and / or chromosomal regions having one or more oligonucleotide tags (e.g., oligopaints) and / or read molecules bound thereto may be selected and / or screened for use with a microscope, spectrophotometer, tube luminescence or plate luminescence, X-ray film, scintillator, fluorescence-activated cell sorting (FACS) device, microfluidic device, etc.
[0107] In some embodiments of any aspect, the detection molecule comprises a fluorophore or a fluorescent compound. Systems and devices for fluorescence measurement are well known in the art. Fluorescence measurement requires a light source that emits light having an appropriate absorption or excitation wavelength. The absorption or excitation wavelength of the compounds described herein is approximately 300 to 800 nm. In some embodiments of any aspect, the light source emits light having a wavelength of 300 to 870 nm, which is essentially formed therefrom. The light comes into contact with the sample and excites electrons of a specific substance (also called a fluorophore) within the sample, causing the substance to emit light (luminescence) in the form of fluorescence.
[0108] A system or device for fluorescence measurement subsequently detects emitted light. In some embodiments, the system or device may include a filter or a monochromator so that only light of a desired wavelength reaches the detector of the system or device. In some embodiments of any aspect, the system or device is configured to detect light that includes, is essentially configured with, or is configured with a wavelength of 300 to 800 nm. In some embodiments of any aspect, the system or device is configured to detect light that includes, is essentially configured with, or is configured with a wavelength of 300 to 800 nm. Suitable systems and devices are commercially available and may include, for example, CRAIC (San Dimas, CA)'s 20 / 30 PV™ Microspectrometer or 508 PV™ Microscope Spectrometer, Duetta™, FluoroMax™, Fluorolog™, QuantaMaster 8000™, DeltaFlex™, DeltaPro, or Horiba (Irvine, CA)'s Nanolog™, or SP8 Lightning™, SP8 Falcon™, SP8 Dive™, TCS SPE™, HCS A™, or Leica (Buffalo Grove, IL)'s TCS SP8 X™.
[0109] In some embodiments of any modality, the results of hybridization in situ can be detected and recorded using routine methods known in the art with fluorescence microscopy. Alternatively, a digital (computer-implemented) fluorescence microscope with image-processing capabilities may be used. Two well-known systems for imaging FISH of chromosomes combined with multiple color labels include multiplex-FISH (M-FISH) and spectral karyotype analysis (SKY). See the following literature: Schrock et al. (1996) Science 273:494; Roberts et al. (1999) Genes Chrom. Cancer 25:241; Fransz et al. (2002) Proc. Natl. Acad. Sci. USA 99:14584; Bayani et al. (2004) Curr. Protocol. Cell Biol. 22.5.1-22.5.25; Danilova et al. (2008) Chromosoma 117:345; U.S. Patent No. 6,066,459; and FISH TAG™ DNA Multicolor Kit Instruction Manual for Review of Methods for Chromosome Painting and Detection of Painted Chromosomes (Molecular Probes).
[0110] In certain exemplary embodiments, images of fluorescently labeled chromosomes are detected and recorded using a computer imaging system such as the Applied Imaging Corporation CytoVision™ System with modifications (e.g., software, Chroma 84000 filter set, and enhanced filter wheel). Other suitable systems include computer imaging systems using a cooled CCD camera coupled to a Zeiss Axiohot microscope (Photometrics, NU200 series equipped with a Kodak KAF 1400 CCD) with images processed as described in the literature [Ried et al. (1992) Proc. Natl. Acad. Sci. USA 89:1388]. Other suitable imaging and analysis systems are described in the literature above [Schrock et al. (previous edition) and Speicher et al. (1996) Nature Genet. 12:368]. In some embodiments of any modality, the oligonucleotide tag (e.g., oligopaint) is visualized with a super-resolution microscope (e.g., stochastic optical reconstruction microscope (STORM) imaging).
[0111] The in situ hybridization method described herein may be performed on various biological or clinical samples in cells at any (or all) phase(s) of the cell cycle (e.g., mitosis, meiosis, interphase, G0, G1, S, and / or G2). Examples include all types of cell cultures, animal or plant tissues, peripheral blood lymphocytes, buccal smears, contact products prepared from uncultured primary tumors, cancer cells, bone marrow, cells obtained from biopsies or cells in body fluids (e.g., blood, urine, sputum, etc.), cells from amniotic fluid, cells from maternal blood (e.g., fetal cells), cells from testes and ovaries, etc. Samples are prepared for the analysis of the present invention using conventional techniques and generally depend on the source from which the sample or specimen is taken. These examples should not be construed as limiting the types of samples applicable to the methods and / or compositions described herein.
[0112] Hybridization of the oligonucleotide tag of the present invention (e.g., oligopaint) to a target chromosome sequence can be achieved by standard in situ hybridization (ISH) techniques (e.g., see the following literature: Gall and Pardue (1981) Meth. Enzymol. 21:470; Henderson (1982) Int. Review of Cytology 76:1). Generally, ISH comprises the following key steps: (1) fixation of the biological structure to be analyzed (e.g., chromosome spread), (2) pre-hybridization treatment of the biological structure to increase accessibility to target DNA (e.g., denaturation with heat or alkali), (3) selective pre-hybridization treatment to reduce non-specific binding (e.g., by blocking the hybridization ability of repeat sequences), and (4) hybridization of the nucleic acid mixture to the nucleic acid of the biological structure or tissue; (5) washing after hybridization to remove unbound nucleic acid fragments during hybridization and (6) detection of hybridized labeled oligonucleotides (e.g., hybridized oligonucleotide tags, e.g., oligopaints). The reagents used in each of these steps and the conditions of their use vary depending on the specific circumstances. For example, step 3 is not always necessary because the recognition domain described herein may be designed to avoid repetitive sequences). Hybridization conditions are also described in U.S. Patent No. 5,447,841. It will be understood that various variations of in situ hybridization protocols and conditions are known and may be used by practitioners in conjunction with the present invention in accordance with the guidelines provided herein.
[0113] As used herein, the term "hybridization" refers to the process in which two single-stranded polynucleotides non-covalently combine to form a stable double-stranded polynucleotide. The term "hybridization" may also refer to triple-stranded hybridization. The resulting (generally) double-stranded polynucleotide is a "hybrid" or "duplex." "Hybridization conditions" will generally involve salt concentrations of less than about 1 M, more commonly less than about 500 mM, and much more commonly less than about 200 mM. Hybridization temperatures may be as low as 5°C, but typically exceed 22°C, more typically exceed about 30°C, and often exceed about 37°C. Hybridization is generally performed under strict conditions, that is, conditions in which the probe hybridizes to its target subsequence. Strict conditions are sequence-dependent and vary depending on the situation. Longer fragments may require higher hybridization temperatures for specific hybridization. Since other factors, including base composition, complementary strand length, the presence of organic solvents, and the degree of base mismatch, can affect the severity of hybridization, the combination of parameters is more important than any single absolute measure. Generally, strict conditions are selected to be about 5°C lower than the Tm for a specific sequence at defined ionic strength and pH. Exemplary strict conditions include a salt concentration of at least 0.01 M to 1 M or less of Na ion concentration at pH 7.0 to 8.3 and a temperature of at least 25°C. For example, conditions of 5×SSPE (750 mM NaCl, 50 mM Na phosphate, 5 mM EDTA, pH 7.4) and a temperature of 25–30°C are suitable for allele-specific probe hybridization.For strict conditions, see, for example: Sambrook, Fritsche and Maniatis, Molecular Cloning A Laboratory Manual, 2nd Ed. Cold Spring Harbor Press (1989) and Anderson Nucleic Acid Hybridization, 1st Ed., BIOS Scientific Publishers Limited (1999). "Hybridizing specifically to" or "specifically hybridizing to" or similar expressions refer to binding, double-helixing, or hybridizing substantially or exclusively to specific nucleotide sequences or sequences under strict conditions when the sequence in question is present in a complex mixture (e.g., whole cell) of DNA or RNA.
[0114] As used herein, the term “specific binding” refers to a chemical interaction between two molecules, compounds, cells, and / or particles, wherein the first entity binds to the second target entity with greater specificity and affinity than it binds to the third entity that is not the target. In some embodiments, specific binding may refer to the affinity of the first entity for the second target entity, which is at least 10 times, at least 50 times, at least 100 times, at least 500 times, at least 1000 times, or more than the affinity for the third non-target entity. A reagent specific for a given target is one that exhibits specific binding to the target under the analytical conditions used.
[0115] The term “oligonucleotide,” as used herein, is intended to include, but is not limited to, single-stranded DNA or RNA molecules generally produced by synthetic means. The nucleotides of the present invention will typically be naturally occurring nucleotides, such as those derived from adenosine, guanosine, uridine, cytidine, and thymidine. Where an oligonucleotide is referred to as “double-stranded,” it is understood by those skilled in the art that a pair of oligonucleotides exists in a hydrogen-bonded helical array, for example, typically coupled to DNA. In addition to the 100% complementary form of a double-stranded oligonucleotide, the term “double-stranded,” as used herein, also implies a form including structural features such as bulges and loops (see the reference [Stryer, Biochemistry, Third Ed. (1988)], the full text of which is incorporated herein by reference for all purposes). The term “polynucleotide,” as used herein, is intended to include two or more oligonucleotides linked together (e.g., by hybridization, ligation, polymerization, etc.), but is not limited thereto.
[0116] Nucleic acid and ribonucleic acid (RNA) molecules can be isolated from specific biological samples using any of the numerous procedures well known in the art, and specific isolation procedures are selected to suit specific biological samples. For example, freeze-thaw and alkaline lysis procedures may be useful for obtaining nucleic acid molecules from solid materials; heat and alkaline lysis procedures may be useful for obtaining nucleic acid molecules from urine; and protease K extraction may be used to obtain nucleic acids from blood (Roiff, A et al. PCR: Clinical Diagnostics and Research, Springer (1994)).
[0117] In certain exemplary embodiments, a nucleic acid sequence, such as an oligonucleotide tag (e.g., oligopaint), can be amplified using universal primers. The term "universal primers" refers to a set of primers (e.g., forward and reverse primers) that can be used for chain extension / amplification of multiple polynucleotides, for example, the primers hybridize to sites common to multiple polynucleotides. For example, universal primers can be used for the amplification of all, or essentially all, polynucleotides in a single pool. In some embodiments of any aspect, the forward primer and the reverse primer have the same sequence. In some embodiments of any aspect, the sequence of the forward primer is different from the sequence of the reverse primer. In another aspect, multiple universal primers, for example, tens, hundreds, thousands, or more are provided.
[0118] In some embodiments of any aspect, the universal primer may be a temporary primer that can be removed after amplification via enzymatic or chemical cleavage. In some embodiments of any aspect, the universal primer may be a temporary primer that can be removed after amplification via enzymatic or chemical cleavage. In other embodiments, the universal primer may include a modification that is incorporated into the polynucleotide molecule upon chain elongation. Exemplary modifications include, for example, a 3' or 5' end cap, a label (e.g., fluorescein), or a tag (e.g., a tag that facilitates the immobilization or isolation of the polynucleotide, such as biotin).
[0119] In some embodiments of any aspect, the method disclosed herein comprises, for example, amplifying an oligonucleotide sequence comprising an oligonucleotide tag (e.g., an oligopaint). The amplification method may include the step of contacting the nucleic acid with one or more primers (e.g., universal primers) that specifically hybridize to the nucleic acid under conditions that promote hybridization and chain elongation. Exemplary methods for nucleic acid amplification include polymerase chain reaction (PCR) (e.g., Mullis et al. (1986) Cold Spring Harb. Symp. Quant. Biol. 51 Pt 1:263 and Cleary et al. (2004) Nature Methods 1:241; and see U.S. Patents No. 4,683,195 and 4,683,202), anchor PCR, RACE PCR, ligation chain reaction (LCR) (e.g., Landegran et al. (1988) Science 241:1077-1080; and Nakazawa et al. (1994) Proc. Natl. Acad. Sci. USA 91:360-364), self-persistent sequence cloning (Guatelli et al. (1990) Proc. Natl. Acad. Sci. USA 87:1874), and transcription amplification systems (Kwoh et al. amplification methods described in al. (1989) Proc. Natl. Acad. Sci. USA 86:1173), Q-beta replication enzyme (Lizardi et al. (1988) BioTechnology 6:1197), recursive PCR (Jaffe et al. (2000) J. Biol. Chem. 275:2619, and Williams et al. (2002) J. Biol. Chem. 277:7790), U.S. Patents No. 6,391,544, No. 6,365,375, No. 6,294,323, No. 6,261,797, No. 6,124,090 and No. 5,612,199, or any other nucleic acid amplification method using techniques well known to those skilled in the art.In an exemplary embodiment, the method disclosed herein utilizes PCR amplification.
[0120] Generally, a PCR procedure describes gene amplification comprising (i) sequence-specific hybridization of primers for a specific gene or sequence within a nucleic acid sample or library, (ii) successive amplification comprising multiple rounds of annealing, extension, and denaturation using a heat-stable DNA polymerase, and (iii) screening the PCR product for bands of the correct size. The primers used are oligonucleotides of a suitable sequence and of sufficient length to provide polymerization initiation; that is, each primer is specifically designed to be complementary to the strand of the genomic locus to be amplified. In an alternative embodiment, the mRNA levels of the gene expression products described herein may be determined by reverse transcription (RT) PCR and quantitative RT-PCR (QRT-PCR) or real-time PCR methods. RT-PCR and QRT-PCR methods are well known in the art.
[0121] In some embodiments of any aspect, the oligonucleotide tag (e.g., oligopaint) is not necessarily amplified (e.g., via PCR and / or universal priming regions). In some embodiments of any aspect, the described oligonucleotide tag (e.g., oligopaint) is newly ( de novo) can be synthesized and used “directly from the tube.” Methods for synthesizing new oligonucleotides are well known to those skilled in the art. As used herein, “oligonucleotide synthesis” refers to the chemical synthesis of a relatively short nucleic acid fragment having a defined chemical structure. By non-limiting example, methods for oligonucleotide synthesis include phosphoramidite solid-phase synthesis, phosphoramidite synthesis, phosphodiester synthesis, phosphotriester synthesis, or phosphite triester synthesis. For example, see the following: Beaucage et al. Tetrahedron Volume 48, Issue 12, 20 March 1992, Pages 2223-2311; Caruthers, J Biol Chem. 2013 Jan 11, 288(2):1420-7. In some embodiments, each oligonucleotide is synthesized separately. In some embodiments, the entire set of oligonucleotides is synthesized in a single reaction. In some embodiments, a subset of the entire oligonucleotide set is synthesized in a single reaction. In some embodiments, the entire oligonucleotide set is synthesized in a plurality of separate reactions. In some embodiments, the reaction products are isolated, for example, by high-performance liquid chromatography (HPLC) to obtain the desired oligonucleotide in high purity.
[0122] In certain exemplary embodiments, a kit is provided. As used herein, the term “kit” refers to any delivery system for delivering an oligonucleotide tag (e.g., oligopaint), a read molecule, and / or a reagent for carrying out the method described herein. In relation to an analysis, such a kit comprises an enclosure providing one or more of reaction reagents (e.g., an oligonucleotide tag, a read molecule, primers (e.g., primers specific to all present oligonucleotide tags and / or one or more subsets of primers specific to one or more subsets of oligonucleotide tag sequences), primers combined with one or more detectable and / or searchable labels), a support to which the oligonucleotide is combined (e.g., a microarray, a pallet, or the like), and / or supporting materials (e.g., a buffer, written instructions for carrying out the analysis described herein, or the like), and / or a supporting material (e.g., an enclosure providing the like). For example, the kit comprises one or more enclosures (e.g., boxes) containing related reaction reagents and / or support materials for analysis described herein. In one embodiment, the kit of the present invention comprises an oligonucleotide tag (e.g., oligopaint) specific to one or more target nucleotide sequences (e.g., chromosomes) or one or more regions of one or more target nucleotide sequences (e.g., subchromosome regions). In one embodiment, the kit of the present invention comprises a read molecule specific to one or more oligonucleotide tags (e.g., oligopaint). In another embodiment, the kit comprises one or more primer sequences, one or more supports having a plurality of synthetic oligonucleotide sequences attached thereto, and one or more detectable and / or retrievable labels. These contents may be delivered to an intended recipient together or individually.For example, the first container may include a primer sequence for use in analysis, while the second container may include a support to which a plurality of synthetic oligonucleotide sequences are attached.
[0123] In some embodiments of any aspect, the kit provides one or more arrays and / or palettes having a plurality of specific oligonucleotide sequences (e.g., oligonucleotide tags (e.g., oligopaints) and / or read molecules) coupled thereto. In some embodiments of any aspect, the arrays and / or palettes provide a plurality of oligonucleotide tag sequences (e.g., oligopaints) specific to a set of binding patterns in a genome (e.g., the human genome). In some embodiments of any aspect, the arrays or palettes are specific to a predetermined set of chromosomal abnormalities (e.g., translocations, insertions, inversions, deletions, duplications, translocations, aneuploidy, ploidy, complex rearrangements, and telomere loss) associated with one or more disorders described herein. In some embodiments of any aspect, the kit described herein is particularly suitable for diagnostic and / or prognostic use for detecting one or more disorders described herein in a clinical setting (e.g., hospital, medical clinic, clinic, diagnostic laboratory, research laboratory, etc.) (e.g., for patient diagnosis and / or prognosis, prenatal diagnosis and / or prognosis, etc.).
[0124] In some embodiments of any aspect, the kit provides instructions for amplifying a plurality of specific oligonucleotide tag sequences (e.g., oligopaint) provided within the kit. In some embodiments of any aspect, the kit provides instructions for using the amplified oligonucleotide tags (e.g., oligopaint) to label one or more target nucleic acid sequences (e.g., one or more chromosomes or subchromosomal regions) detectably and / or traceably. In some embodiments of any aspect, the kit provides instructions for using oligonucleotide tags (e.g., oligopaint) and read molecules to label one or more target nucleic acid sequences (e.g., one or more chromosomes or subchromosomal regions) detectably and / or traceably. In some embodiments of any aspect, the kit provides instructions for effectively removing one or more of the specific oligonucleotide tag sequences (e.g., oligopaint) during the amplification step by including one or more unlabeled amplification primers that hybridize to one or more oligonucleotide sequences to be removed, thereby ensuring that one or more target nucleic acid sequences are not labeled detectably and / or traceably.
[0125] In some embodiments of any aspect, the system and method described herein may be implemented in any type of hardware and / or software and may be a pre-programmed general-purpose computing device. For example, the system may be implemented using a server, a personal computer, a portable computer, a thin client, or any suitable device or devices. The disclosure and / or components thereof may be a single device at a single location, or a plurality of devices at a single or multiple locations connected together wirelessly or via any communication medium such as an electric cable or a fiber optic cable using any suitable communication protocol.
[0126] It should also be noted that the present disclosure is described and discussed herein as having a plurality of modules that perform specific functions. It should be understood that such modules are described schematically based on function solely for the purpose of clarity and do not necessarily represent specific hardware or software. In this regard, these modules may be hardware and / or software implemented to substantially perform the specific functions discussed. Additionally, modules may be combined together within the present disclosure or divided into additional modules based on specific desired functions. Accordingly, the present disclosure should not be interpreted as limiting the invention, but should be understood as merely presenting one exemplary embodiment.
[0127] A computing system may include a client and a server. The client and the server are typically located far apart from each other and generally interact through a communication network. The relationship between the client and the server arises thanks to computer programs running on their respective computers that have a client-server relationship with each other. In some implementations, the server transmits data (e.g., an HTML page) to the client device (for the purpose of displaying data on the client device and receiving user input from a user interacting with the client device). Data generated on the client device (e.g., the result of user interaction) can be received from the client device by the server.
[0128] An embodiment of the subject matter of the invention described herein may be implemented in a computing system comprising, for example, a data server, a backend component, a middleware component, for example, an application server, or a frontend component, for example, a client computer having a graphical user interface or a web browser through which a user can interact with the embodiment of the subject matter of the invention described herein, or any combination of one or more such backend, middleware, or frontend components. Components of the system may be interconnected by any form or medium of digital data communication, for example, a communication network. Examples of communication networks include local area networks (“LAN”) and wide area networks (“WAN”), mutual networks (e.g., the Internet), and peer-to-peer networks (e.g., ad hog peer-to-peer networks).
[0129] Implementations of the subject matter and operation of the invention described herein may be implemented in digital electronic circuits, or in computer software, firmware, or hardware, or in a combination of one or more of these, comprising structures and structural equivalents disclosed herein. Implementations of the subject matter of the invention described herein may be implemented in one or more computer programs, that is, in one or more modules of computer program instructions coded in a computer storage medium for execution by a data processing device or for controlling the operation thereof. Alternatively or additionally, program instructions may be coded in artificially generated radio signals, for example, machine-generated electrical, optical, or electromagnetic signals generated to code information to be transmitted to a suitable receiver device for execution by a data processing device. The computer storage medium may be a computer-readable storage device, a computer-readable storage substrate, a random or serial access memory array or device, or a combination of one or more of these, or may be included therein. Furthermore, although the computer storage medium is not a radio signal, the computer storage medium may be a source or destination of computer program instructions coded in an artificially generated radio signal. A computer storage medium may also be one or more individual physical components or media (e.g., multiple CDs, disks, or other storage devices) or may be included therein.
[0130] The operations described in this specification may be implemented as operations performed by a "data processing apparatus" on data stored in one or more computer-readable storage devices or received from other sources.
[0131] The term “data processing device” encompasses all types of data processing devices, devices, and machines, including, for example, programmable processors, computers, system-on-chips, or various or combinations thereof of the above. A device may include special-purpose logic circuits, for example, FPGAs (Field Programmable Gate Arrays) or ASICs (Application-Specific Integrated Circuits). A device may also include, in addition to hardware, code that creates an execution environment for the computer program in question, for example, processor firmware, a protocol stack, a database management system, an operating system, a cross-platform runtime environment, a virtual machine, or a combination of one or more of these. The device and execution environment may realize various other computing model infrastructures, such as web services, distributed computing, and grid computing infrastructures.
[0132] A computer program (also known as a program, software, software application, script, or code) may be written in any form of programming language, including compiled or interpreted languages, declarative or procedural languages, and may be distributed in any form, including a standalone program or modules, components, subroutines, objects, or other units suitable for use in a computing environment. A computer program may correspond to a file in a file system, but is not necessarily so. A program may be stored in a part of a file containing other programs or data (e.g., one or more scripts stored in a markup language document), a single file dedicated to that program, or multiple coordinated files (e.g., files storing one or more modules, subprograms, or parts of code). A computer program may be distributed to be executed on a single computer or at a single site, or on multiple computers distributed across multiple sites and interconnected by a communication network.
[0133] The processes and logic flows described in this specification may be performed by one or more programmable processors that execute one or more computer programs to perform operations by operating on input data and generating outputs. The processes and logic flows may be performed by special-purpose logic circuits, for example, a Field Programmable Gate Array (FPGA) or an Application-Specific Integrated Circuit (ASIC), and the device may be implemented as described above.
[0134] Processors suitable for executing computer programs include, for example, general-purpose and special-purpose microprocessors, and any one or more processors of any type of digital computer. Generally, the processor receives instructions and data from read-only memory or random access memory, or both. Essential components of a computer are a processor for performing actions according to instructions and one or more memory devices for storing instructions and data. Generally, the computer also includes one or more mass storage devices for storing data, for example, magnetic, magneto-optical disks, or optical disks, or is operably connected to receive data from the foregoing, transmit data to them, or both. However, the computer does not require these devices. Additionally, the computer may be embedded in other devices, to name just a few, for example, mobile phones, personal information terminals (PDAs), mobile audio or video players, game consoles, Global Positioning System (GPS) receivers, or portable storage devices (for example, USB (Universal Serial Bus) flash drives). Devices suitable for storing computer program instructions and data include all forms of non-volatile memory, media, and memory devices, for example, semiconductor memory devices, e.g., EPROM, EEPROM, and flash memory devices; magnetic disks, e.g., internal hard disks or removable disks; magneto-optical disks; and CD-ROM and DVD-ROM disks. Processors and memory may be complemented by or integrated with special-purpose logic circuits.
[0135] For convenience, the meanings of some terms and phrases used in the specification, embodiments, and appended claims are provided below. Unless otherwise stated or implied by the context, the following terms and phrases include the meanings provided below. Definitions are provided to aid in describing specific embodiments and are not intended to limit the claimed invention, because the scope of the invention is limited only by the claims. Unless otherwise defined, all technical and scientific terms used in this specification have the same meaning as generally understood by those skilled in the art to which the invention pertains. In the event of any apparent discrepancy between the use of terms in the relevant art and the definitions provided in this specification, the definitions provided in the specification shall prevail.
[0136] For convenience, specific terms used in the specification, embodiments, and appended claims are gathered herein.
[0137] As used herein, the term “chromosome” refers to a support for a gene carrying heredity in a living cell, comprising DNA, proteins, RNA, and other related factors. The conventional international system for identifying and numbering chromosomes of the human genome is used herein. The size of individual chromosomes may vary within a multi-chromosome genome and from genome to genome. Chromosomes may be obtained from any species. Chromosomes may be obtained from adult subjects, adolescent subjects, or infant subjects; from unborn subjects (e.g., fetuses, via prenatal testing such as amniocentesis, chorionic villus sampling, etc., or fetuses, e.g., during fetal surgery); from biological samples (e.g., biological tissues, body fluids, or cells (e.g., sputum, blood, blood cells, tissue or fine needle biopsy samples, urine, cerebrospinal fluid, peritoneal fluid, and pleural fluid, or cells derived therefrom); or from cell culture samples (e.g., primary cells, immortalized cells, partially immortalized cells, etc.). In certain exemplary embodiments, one or more chromosomes may be, but are not limited to, Homo, Drosophila, Caenorhabditis, Danio, Cypinus, Equus, Canis, Ovis, Ocorynchus, It can be obtained from one or more genera including Salmo, Bos, Sus, Gallus, Solanum, Triticum, Oryza, Zea, Hordeum, Musa, Avena, Populus, Brassica, Saccharum, etc.
[0138] The term “chromosome banding,” as used herein, refers to differential staining of chromosomes that results in a transverse band pattern of distinguishable (e.g., differently or alternately colored) regions characteristic of individual chromosomes or chromosomal regions (i.e., “banding pattern”). Conventional banding techniques include G-banding (Gimsa staining), Q-banding (quinacrine mustard staining), R-banding (reverse Giemsa), and C-banding (centromere banding).
[0139] As used herein, the term “karyotype” refers to the chromosomal characteristics of individual cells, cell lines, or genomes of a given species, as defined by both the number and shape of the chromosomes. A karyotype may exhibit various chromosomal rearrangements, including but not limited to translocations, insertion translocations, inversions, deletions, duplications, translocations, aneuploidy, complex rearrangements, telomere loss, etc. Generally, a karyotype is represented as a systematic arrangement of chromosomes in an inclined or metaphase (or contracted) state in a micrograph or computer-generated image. Interphase chromosomes may also be examined.
[0140] As used herein, the terms “chromosomal aberration” or “chromosome abnormality” refer to a deviation between the structure of a target chromosome or karyotype and a normal (i.e., non-aberrant) homologous chromosome or karyotype. The deviation may be a single base pair or many base pairs. When referring to a chromosome or karyotype, the terms “normal” or “non-aberrant” refer to a karyotype or banding pattern found in healthy individuals of a particular species and sex. Chromosomal abnormalities may be numerical or structural in nature and include, but are not limited to, aneuploidy, polyploidy, inversion, translocation, deletion, duplication, etc. Chromosomal abnormalities may be correlated with the presence of a pathological condition or a predisposition to developing a pathological condition. Chromosomal abnormalities and / or abnormalities may also refer to changes unrelated to disease, disorder, and / or phenotypic change. Such abnormalities and / or abnormalities may occur rarely or at a low frequency (e.g., a few percent of the population (e.g., polymorphism)).
[0141] Disorders associated with one or more chromosomal abnormalities, but not limited to these, include autosomal abnormalities (e.g., trisomy (Down syndrome (chromosome 21)), Edwards syndrome (chromosome 18), Patau syndrome (chromosome 13), trisomy 9, Wakani syndrome (chromosome 8), trisomy 22 / cat-eye syndrome, trisomy 16); Monosomal and / or deletions (Wolf-Hirschhorn syndrome (chromosome 4), Cri du chat / chromosome 5q deletion syndrome (chromosome 5), Williams syndrome (chromosome 7), Jacobsen syndrome (chromosome 11), Miller-Dicker syndrome / Smith-Magenis syndrome (chromosome 17), DeGeorge syndrome (chromosome 22), genomic imprinting (Angelmann syndrome / Prader-Willi syndrome (chromosome 15))); X / Y-linked abnormalities (e.g., monosomal (Turner syndrome (XO), trisomy or tetrasomal and / or other karyotypes or mosaics (Klinefelter syndrome (47(XXY)), 48(XXYY), 48(XXXY), 49(XXXYY), 49(XXXXY), Triple X syndrome (47(XXX)), 48(XXXX), 49(XXXXX), 47(XYY), 48(XYYY), 49(XYYYY), 46(XX / XY)); translocations (e.g., leukemia or lymphoma (e.g., Burkitt lymphoma t(8 MYC; 14 IGH)), follicular lymphoma t(14 IGH; 18 BCL2), mantle cell lymphoma / multiple myeloma t(11 CCND1; 14 IGH), anaplastic large cell lymphoma t(2 ALK; 5 NPM1), acute lymphoblastic leukemia) or myeloid (e.g., Philadelphia chromosome t(9 ABL; 22 BCR), acute myeloid leukemia with maturation t(8 RUNX1T1; 21 RUNX1), acute promyelocytic leukemia t(15 PML, 17 RARA), acute megakaryoblastic leukemia t(1 RBM15; 22 MKL1))) or other (e.g., Ewing sarcoma t(11 FiI1; 22 EWS), synovial sarcoma t(x SYT;Includes 18 SSX), dermatofibrosarcoma protuberans t(17 COL1A1; 22 PDGFB), myxoid liposarcoma t(12 DDIT3; 16 FUS), desmoplastic small round cell tumor t(11 WT1; 22 EWS), alveolar rhabdomyosarcoma t(2 PAX3; 13 FOXO1) t(1 PAX7; 13 FOXO1))); gonadal dysplasia (e.g., mixed gonadal dysplasia, XX gonadal dysplasia); and other abnormalities (e.g., fragile X syndrome, single-parent dyssomnia). Disorders associated with one or more chromosomal abnormalities include, but are not limited to, Beckwith-Wiedmann syndrome, branchio-oto-renal syndrome, Creed-du-Chat syndrome, De Lange syndrome, holoprosencephaly, Rubinstein-Taybi syndrome, and WAGR syndrome.
[0142] Disorders associated with one or more chromosomal abnormalities also include cell proliferation disorders (e.g., cancer). As used herein, the term “cell proliferation disorder” includes disorders characterized by the undesirable or inappropriate proliferation of one or more subset(s) of cells in a multicellular organism. The term “cancer” refers to various types of malignant neoplasms, most of which can invade surrounding tissues and metastasize to other sites (see, e.g., PDR Medical Dictionary 1st edition, 1995). The terms “neoplasm” and “tumor” refer to abnormal tissue that grows by cell proliferation at a faster rate than normal and continues to grow even after the stimulus that initiated the proliferation is removed (see, e.g., PDR Medical Dictionary 1st edition, 1995). Such abnormal tissue exhibits a partial or complete lack of structural organization and functional coordination with normal tissue, which may be benign (i.e., benign tumor) or malignant (i.e., malignant tumor).
[0143] Disorders associated with one or more chromosomal abnormalities also include acoustic neuroma, acquired brain injury, Alzheimer's disease, amyotrophic lateral sclerosis, aneurysm, aphasia, arteriovenous malformation, attention deficit hyperactivity disorder, autism, Batten disease, Behcet's disease, blepharospasm, brain tumor, cerebral palsy, Charcot-Marie-Tooth disease, Chiari malformation, CIDP, non-Alzheimer's dementia, autonomic dysfunction, dyslexia, speech disorder, dystonia, epilepsy, essential tremor, Friedrich's ataxia, Gaucher disease, Guillain-Barré syndrome, headache, migraine, Huntington's disease, hydrocephalus, Meniere's disease, motor neuron disease, multiple sclerosis, muscular dystrophy, myasthenia gravis, narcolepsy, Parkinson's disease, peripheral neuropathy, progressive It includes brain disorders including, but not limited to, progressive supranuclear palsy, restless legs syndrome, Rett syndrome, schizophrenia, Shy Drager syndrome, stroke, subarachnoid hemorrhage, Sydenham's syndrome, Tay-Sachs disease, Tourette syndrome, transient ischemic attack, transverse myelitis, trigeminal neuralgia, tuberous sclerosis, and von Hippel-Lindau syndrome.
[0144] The terms "decrease," "reduced," "reduction," or "inhibit" are all used herein to mean a reduction by a statistically significant amount. In some embodiments, “reduce,” “reduction,” “decrease,” or “inhibit” generally means a reduction of at least 10% compared to a reference level (e.g., absence of a given therapeutic agent or agent) and may include, for example, at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or greater reduction. As used herein, “reduction” or “inhibition” does not include complete inhibition or reduction compared to a reference level. "Complete suppression" is 100% suppression compared to the reference level. The reduction can preferably be lowered to a level acceptable within the normal range for a given disorder-free individual.
[0145] The terms "increased," "increase," "enhance," or "activate" are all used herein to mean an increase by a statically significant amount. In some embodiments, the terms “increased,” “increase,” “enhance,” or “activate” may mean an increase of at least 10% compared to a reference level, e.g., at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or up to 100% including these, or any increase between 10% and 100%, or at least about 2 times, or at least about 3 times, or at least about 4 times, or at least about 5 times, or at least about 10 times, or any increase of 2 to 10 times or more compared to a reference level. With respect to a marker or symptom, “increase” is a statistically significant increase of such level.
[0146] In some embodiments of any aspect, the reference sample or level is the level of the sample or the sample itself prior to contact with the composition described herein. In some embodiments of any aspect, the reference sample or level is the level of the sample or composition described herein prior to contact with the sample. In some embodiments of any aspect, the reference may be a sample contacted with a composition that does not contain a detection molecule. In some embodiments of any aspect, the reference may be a sample contacted with a composition that contains a recognition domain not specific to the sample. In some embodiments of any aspect, the reference may also be a level obtained from a control sample, a pooled sample of a control entity, or a numerical value or range of values based thereon.
[0147] As used herein, “subject” means human or animal. Generally, animals are vertebrates such as primates, rodents, domestic animals, or game animals. Primates include chimpanzees, cynomolgus monkeys, spider monkeys, macaques, e.g., rhesus monkeys. Rodents include mice, rats, woodchucks, ferrets, rabbits, and hamsters. Domestic and game animals include cattle, horses, pigs, deer, bison, buffalo, feline species, e.g., domestic cats, canine species, e.g., dogs, foxes, wolves, avian species, e.g., chickens, emus, ostriches, and fish, e.g., trout, catfish, and salmon. In some embodiments, the subject is a mammal, e.g., a primate, e.g., a human. The terms “individual,” “patient,” and “subject” are used interchangeably herein.
[0148] Preferably, the subject is a mammal. The mammal may be a human, a non-human primate, a mouse, a rat, a dog, a cat, a horse, or a cow, but is not limited to these examples.
[0149] As used herein, the terms “protein” and “polypeptide” are used interchangeably herein to denote a series of amino acid residues connected to one another by peptide bonds between the alpha-amino and carboxyl groups of adjacent residues. The terms “protein” and “polypeptide” refer to polymers of amino acids, including modified amino acids (e.g., phosphorylated, glycosylated, etc.) and amino acid analogs, regardless of size or function. While “protein” and “polypeptide” are often used in relation to relatively large polypeptides, the term “peptide” is often used in relation to small polypeptides, but the use of these terms overlaps in the art. The terms “protein” and “polypeptide” are used interchangeably herein when referring to gene products and fragments thereof. Accordingly, exemplary polypeptides or proteins include gene products, naturally occurring proteins, homologs, orthologs, paralogs, fragments and other equivalents, variants, fragments and analogs of the foregoing.
[0150] In the various embodiments described herein, variants (naturally occurring or otherwise), alleles, homologs, conservedly modified variants, and / or conserved substitution variants of any specific polypeptide described are further considered to be included. With respect to amino acid sequences, those skilled in the art will recognize that individual substitutions, deletions, or additions to a nucleic acid, peptide, polypeptide, or protein sequence that change a single amino acid or a small proportion of amino acids in the coded sequence constitute a “conservedly modified variant,” wherein the modification results in the substitution of an amino acid with a chemically similar amino acid while maintaining the desired activity of the polypeptide. Such conservedly modified variants are polymorphic variants, interspecies homologs, and alleles consistent with the present disclosure, and are not excluded.
[0151] A given amino acid may be replaced with a residue having similar physicochemical properties, for example, by substituting one aliphatic residue with another (e.g., Ile, Val, Leu, or Ala with any one other), or by substituting one polar residue with another (e.g., substitution between Lys and Arg; Glu and Asp; or Gln and Asn). Other such conservative substitutions, for example, substitution of the entire region having similar hydrophobic properties, are well known. Polypeptides containing conservative amino acid substitutions may be tested by any of the analyses described herein to confirm that the desired activity, for example, the activity and specificity of the natural or reference polypeptide, is maintained.
[0152] Amino acids can be classified according to the similarity of their side chain characteristics (AL Lehninger, in Biochemistry, second ed., pp. 73-75, Worth Publishers, New York (1975)): (1) Non-polar: Ala(A), Val(V), Leu(L), Ile(I), Pro(P), Phe(F), Trp(W), Met(M); (2) Non-charged polar: Gly(G), Ser(S), Thr(T), Cys(C), Tyr(Y), Asn(N), Gln(Q); (3) Acidic: Asp(D), Glu(E); (4) Basic: Lys(K), Arg(R), His(H). Alternatively, naturally occurring residues can be divided into the following groups based on common side chain characteristics: (1) Hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile; (2) Neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) Acidic: Asp, Glu; (4) Basic: His, Lys, Arg; (5) Residues affecting chain orientation: Gly, Pro; (6) Aromatic: Trp, Tyr, Phe. Non-conservative substitutions involve exchanging a member of one of these classes for another. Specific conservative substitutions are, for example, Ala to Gly or Ser; Arg to Lys; Asn to Gln or His; Asp to Glu; Cys to Ser; Gln to Asn; Glu to Asp; Gly to Ala or Pro; His to Asn or Gln; Ile to Leu or Val; Leu to Ile or Val; Lys to Arg, Gln, or Glu; Met to Leu, Tyr, or Ile; Phe to Met, Leu, or Tyr; Ser to Thr; Thr to Ser; Trp to Tyr; Tyr to Trp; and / or includes substitution of Phe with Val, Ile, or Leu.
[0153] In some embodiments, the polypeptide (or nucleic acid encoding such polypeptide) described herein may be a functional fragment of one of the amino acid sequences described herein. As used herein, “functional fragment” is a fragment or segment of a peptide that retains at least 50% of the wild-type reference polypeptide activity according to the analysis described below in this specification. The functional fragment may include a conservative substitution of the sequence disclosed herein.
[0154] In some embodiments, the polypeptide described herein may be a variant of the sequence described herein. In some embodiments, the variant is a conservedly modified variant. Conservedly substituting variants may be obtained, for example, by mutations in the natural nucleotide sequence. As referred to herein, a “variant” is substantially homologous to the natural or reference polypeptide but has an amino acid sequence different from the natural or reference polypeptide due to one or more deletions, insertions, or substitutions. A variant polypeptide-coding DNA sequence comprises a sequence encoding a variant protein or a fragment thereof that retains activity, containing one or more additions, deletions, or substitutions of nucleotides compared to the natural or reference DNA sequence. Various PCR-based site-specific mutagenesis approaches are known in the art and can be applied by those skilled in the art.
[0155] A variant amino acid or DNA sequence may be at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more identical to the natural or reference sequence. For example, the degree of homology (percentage of identity) between the natural sequence and the variant sequence can be determined by comparing two sequences using a free computer program commonly used for this purpose on the World Wide Web (e.g., BLASTp or BLASTn with default settings).
[0156] Modification of natural amino acid sequences can be achieved by any number of techniques known to those skilled in the art. Mutations can be introduced at specific loci by synthesizing oligonucleotides containing the mutant sequence, for example, which are adjacent to a restriction site that enables ligation to a fragment of the natural sequence. After ligation, the resulting reconstructed sequence codes for an analog having a desired amino acid insertion, substitution, or deletion. Alternatively, an oligonucleotide-designation-specific mutagenesis procedure can be used to provide a modified nucleotide sequence having a specific codon altered according to the required substitution, deletion, or insertion. Techniques for such modifications are very well established and include, for example, those disclosed in the following literature, the full text of which is incorporated herein by reference: Walder et al. (Gene 42:133, 1986); Bauer et al. (Gene 37:73, 1985); Craik (BioTechniques, January 1985, 12-19); Smith et al. (Genetic Engineering: Principles and Methods, Plenum Press, 1981); and U.S. Patents No. 4,518,584 and No. 4,737,462. Any cysteine residue not involved in maintaining the proper shape of the polypeptide may also be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent abnormal cross-linking. Conversely, cysteine bond(s) may be added to the polypeptide to improve stability or promote oligomerization.
[0157] As used herein, the terms “nucleic acid” or “nucleic acid sequence” refer to any molecule, preferably a polymeric molecule, comprising units of ribonucleic acid, deoxyribonucleic acid, or analogs thereof. The nucleic acid may be single-stranded or double-stranded. A single-stranded nucleic acid may be one nucleic acid strand of denatured double-stranded DNA. Alternatively, it may be a single-stranded nucleic acid not derived from double-stranded DNA. In some embodiments of any aspect, the single-stranded nucleic acid is in vitro ( in-vitro ) is generated by reverse transcription following transcription. In some embodiments of any mode, single-stranded nucleic acid is generated by exposure to a nicking endonuclease. In some embodiments of any mode, single-stranded nucleic acid is newly ( de novo ) is synthesized. In one embodiment, the nucleic acid may be DNA. In another embodiment, the nucleic acid may be RNA. Suitable DNA may include, for example, genomic DNA or cDNA. Suitable RNA may include, for example, mRNA.
[0158] The term “expression” refers to cellular processes involved in producing RNA and proteins and, where appropriate, secreting proteins, and includes, but is not limited to, transcription, transcriptome processing, translation and protein folding, modification and processing, for example, where applicable. Expression may refer to the transcription and stable accumulation and / or translation of the nucleic acid fragment of the present invention or sense (mRNA) or antisense RNA derived from the fragments into a polypeptide.
[0159] In some embodiments, the expression of the biomarker(s), target(s), or gene / polypeptide described herein is tissue-specific. In some embodiments, the expression of the biomarker(s), target(s), or gene / polypeptide described herein is global. In some embodiments, the expression of the biomarker(s), target(s), or gene / polypeptide described herein is systemic.
[0160] "Expression products" include RNA transcribed from a gene and polypeptides obtained by translation of mRNA transcribed from a gene. The term "gene" means a nucleic acid sequence (DNA) that is transcribed into RNA in vitro or in vivo when operably linked to an appropriate regulatory sequence. A gene may or may not include regions before and after a coding region, e.g., a 5' untranslated (5'UTR) or "leader" sequence and a 3' UTR or "trailer" sequence, as well as interpositional sequences (introns) between individual coding segments (exons).
[0161] In some embodiments, the method described herein relates to the step of measuring, detecting, or determining the level of at least one target molecule. As used herein, the terms “detecting” or “measuring” refer to indicating the presence of an analyte in a sample by observing a signal, e.g., a probe, a label, or a target molecule. Any method known in the art for detecting a specific label moiety may be used for detection. Exemplary detection methods include, but are not limited to, spectroscopic, fluorescence, photochemical, biochemical, immunochemical, electro-optical, or chemical methods. In some embodiments of any aspect, the measurement may be a quantitative observation.
[0162] In some embodiments of any modality, polypeptides, nucleic acids, or cells as described herein may be engineered. As used herein, "engineered" refers to a modality engineered by human hands. For example, if at least one modality of a polypeptide, for example, its sequence, is engineered by human hands and differs from the modality found in nature, the polypeptide is considered "engineered." As is common practice and understood by those skilled in the art, the offspring of an engineered cell are generally still referred to as "engineered," even though the actual engineering was performed on the previous entity.
[0163] In some embodiments of any aspect, the nucleic acid described herein (e.g., oligonucleotide tags, e.g., oligopaint) is exogenous. In some embodiments of any aspect, the nucleic acid described herein (e.g., oligonucleotide tags, e.g., oligopaint) is ectopic. In some embodiments of any aspect, the nucleic acid described herein (e.g., oligonucleotide tags, e.g., oligopaint) is not endogenous.
[0164] The term "exogenous" refers to a substance present in a cell other than its natural source. As used herein, the term "exogenous" may refer to nucleic acids (e.g., nucleic acids encoding polypeptides) or polypeptides introduced into a biological system, such as a cell or organism, by a process involving human hands, wherein, generally, said nucleic acids or polypeptides are not found within said system and said nucleic acids or polypeptides are intended to be introduced into said cell or organism. Alternatively, "exogenous" may refer to nucleic acids or polypeptides introduced into a biological system, such as a cell or organism, by a process involving human hands, wherein said nucleic acids or polypeptides are found in said system in relatively small amounts and are intended to increase the amount of said nucleic acids or polypeptides within said cell or organism, e.g., to produce ectopic expression or levels. In contrast, the term "endogenous" refers to a substance distinct from a biological system or cell. As used herein, "ectopic" refers to a substance found in an abnormal location and / or amount. Ectopic material is generally found in a given cell, but may be found in much smaller amounts and / or at different times. Ectopicity also includes substances such as polypeptides or nucleic acids that are not naturally found or expressed in a given cell in a natural environment.
[0165] As used herein, “contacting” refers to any suitable means for delivering or exposing an agent to at least one cell. Exemplary delivery methods include, but are not limited to, direct delivery into a cell culture medium, perfusion, injection, or other delivery methods well known to those skilled in the art. In some embodiments, contacting includes physical human activity, e.g., injection; dispensing, mixing, and / or pouring; and / or manipulation of a delivery device or machine.
[0166] The terms "statistically significant" or "significantly" indicate statistical significance and generally refer to a difference of 2 standard deviations (2SD) or more.
[0167] Except in operating examples or where otherwise indicated, all numbers representing the amounts of ingredients or reaction conditions used herein shall be understood as modified by the term “about” in all cases. When used in relation to percentages, the term “about” may mean ±1%.
[0168] As used herein, the term "comprising" means that other elements may also exist in addition to the defined elements presented. The use of "comprising" indicates inclusion, not limitation.
[0169] The term "consisting of" refers to the composition, method, and each of the components thereof as described herein, excluding any elements not mentioned in the description of the embodiments.
[0170] As used herein, the term “consisting essentially of” refers to elements necessary for a given embodiment. This term allows for the presence of additional elements that do not substantially affect the basic, novel, or functional characteristics(s) of the embodiments of the invention.
[0171] As used herein, the term “corresponding to” refers to an amino acid or nucleotide at an enumerated position in the first polypeptide or nucleic acid, or an amino acid or nucleotide equivalent to an enumerated amino acid or nucleotide in the second polypeptide or nucleic acid. The equivalent enumerated amino acid or nucleotide may be determined by alignment of candidate sequences using a homology program known in the art, for example, BLAST.
[0172] The singular terms "a," "an," and "the" include plural referents unless the context clearly indicates otherwise. Similarly, the word "or" is intended to include "and" unless the context clearly indicates otherwise. Methods and materials similar or equivalent to those described herein may be used to practice or test the present invention, but suitable methods and materials are described below. The abbreviation "eg" is derived from the Latin exempli gratia and is used herein to indicate a non-limiting example. Thus, the abbreviation "eg" is synonymous with the term "for example."
[0173] The grouping of alternative elements or embodiments of the invention disclosed herein shall not be construed as a limitation. Each member of a group may be referenced and claimed individually or in any combination with other members of the group or other elements found in this specification. One or more members of a group may be included in or removed from a group for reasons of convenience and / or patentability. Where any such inclusion or removal occurs, the specification shall be deemed to include the modified group and satisfy all written descriptions of the Markush groups used in the appended claims.
[0174] Unless otherwise defined herein, scientific and technical terms used in connection with this application shall have the meanings generally understood by those skilled in the art to which this disclosure pertains. It should be understood that the present invention is not limited to the specific methodologies, protocols, and reagents, etc. described herein and may vary. The terms used herein are used merely to describe specific embodiments and are not intended to limit the scope of the invention as defined solely by the claims. Definitions of general terms in immunology and molecular biology can be found in the following literature, the entire contents of which are incorporated by reference into this specification: The Merck Manual of Diagnosis and Therapy, 20th Edition, published by Merck Sharp & Dohme Corp., 2018 (ISBN 0911910190, 978-0911910421); Robert S. Porter et al. (eds.), The Encyclopedia of Molecular Cell Biology and Molecular Medicine, published by Blackwell Science Ltd., 1999-2012 (ISBN 9783527600908); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8); Immunology by Werner Luttmann, published by Elsevier, 2006; Janeway's Immunobiology, Kenneth Murphy, Allan Mowat, Casey Weaver (eds.), WWNorton & Company, 2016 (ISBN 0815345054, 978-0815345053); Lewin's Genes XI, published by Jones & Bartlett Publishers, 2014 (ISBN-1449659055); Michael Richard Green and Joseph Sambrook, Molecular Cloning: A Laboratory Manual, 4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., USA (2012) (ISBN 1936113414); Davis et al., Basic Methods in Molecular Biology, Elsevier Science Publishing, Inc., New York, USA (2012) (ISBN 044460149X); Laboratory Methods in Enzymology: DNA, Jon Lorsch (ed.) Elsevier, 2013 (ISBN 0124199542); Current Protocols in Molecular Biology (CPMB), Frederick M. Ausubel (ed.), John Wiley and Sons, 2014 (ISBN 047150338X, 9780471503385), Current Protocols in Protein Science (CPPS), John E. Coligan (ed.), John Wiley and Sons, Inc., 2005; 및 Current Protocols in Immunology (CPI) (John E. Coligan, ADA M Kruisbeek, David H Margulies, Ethan M Shevach, Warren Strobe, (eds.) John Wiley and Sons, Inc., 2003 (ISBN 0471142735, 9780471142737).
[0175] Other terms are defined in this specification within the description of various aspects of the invention.
[0176] All patents and other publications cited throughout this application, including references, published patents, disclosed patent applications, and concurrently pending patent applications, are expressly incorporated by reference into this specification for the purpose of explaining and disclosing methodologies described in such publications that may be used in conjunction with the technology described herein. Such publications are provided solely for the purpose of their disclosure prior to the filing date of this application. In this regard, nothing should be construed as an acknowledgment that the inventor is not qualified to precede such disclosure due to prior art or for any other reason. Any statements regarding dates or representations of the contents of these documents are based on information available to the applicant and do not constitute an acknowledgment of the accuracy of the dates or contents of these documents.
[0177] Description of the embodiments of the present disclosure is not intended to be disclosed in its complete form or to limit the disclosure to the exact form disclosed. While specific embodiments and examples of the present disclosure are described herein for illustrative purposes, as will be recognized by those skilled in the art, various equivalent variations are possible within the scope of the present disclosure. For example, while method steps or functions are presented in a given order, alternative embodiments may perform functions in a different order, or functions may be performed substantially simultaneously. The teachings of the disclosure provided herein may be applied to other appropriate procedures or methods. Various embodiments described herein may be combined to provide additional embodiments. Aspects of the present disclosure may be modified, if necessary, to use the configurations, functions, and concepts of the references and applications to provide other embodiments of the present disclosure. Such changes and other modifications may be made to the present disclosure in light of the detailed description. All such modifications are intended to be included within the scope of the appended claims.
[0178] Certain elements of any of the aforementioned embodiments may be combined with or substituted for elements of other embodiments. Additionally, while the advantages associated with specific embodiments of the present disclosure have been described in the context of such embodiments, other embodiments may also exhibit these advantages, and not all embodiments are required to exhibit such advantages to fall within the scope of the present disclosure.
[0179] The technology described in this specification is further explained by the following examples, which should not be interpreted in any way as an additional limitation.
[0180] Some embodiments of the technology described in this specification may be defined according to any of the numbered items below:
[0181] 1. A method for analyzing at least one target molecule in a sample, wherein the method
[0182] a. A step of contacting the above sample with at least one oligonucleotide tag, wherein each oligonucleotide tag is,
[0183] i. A recognition domain that specifically binds to a target molecule to be analyzed, and
[0184] ii. At least one street including at least one cassette
[0185] It includes, and each cassette,
[0186] 1. A barcode region comprising at least one nucleotide, wherein an anchor region is adjacent to at least one side;
[0187] Herein, the street of each oligonucleotide tag is distinguished from the street of another oligonucleotide tag in step (a) in that at least A. the spatial order of the cassettes within the street is different or B. the sequence of the barcode region is different from the barcode region of another oligonucleotide tag in step (a);
[0188] b. A step of contacting the sample with at least two reading molecules, wherein each reading molecule is
[0189] i. An oligonucleotide that specifically hybridizes with the cassette of at least one oligonucleotide tag used in step (a); and
[0190] ii. Detected molecule,
[0191] Includes;
[0192] Herein, the step wherein the at least two read molecules collectively comprise at least two distinguishable detection molecules;
[0193] c. A step of detecting the relative spatial order of the detection molecules hybridized to at least one oligonucleotide tag, wherein the at least one oligonucleotide tag is hybridized to at least one target molecule, and thereby the relative spatial order of the detection molecules enables identification of which oligonucleotide tag is hybridized to the target molecule at a corresponding location.
[0194] A method including
[0195] 2. With respect to any one of the aforementioned items,
[0196] A method in which the above barcode region comprises 1 to 10 nucleotides.
[0197] 3. With respect to any one of the aforementioned items,
[0198] A method in which the above street includes at least three cassettes.
[0199] 4. With respect to any one of the aforementioned items,
[0200] A method in which the above-mentioned barcode area is adjacent to each mode by an anchor area.
[0201] 5. With respect to any one of the aforementioned items,
[0202] A method in which the anchor region of all the above-mentioned oligonucleotide tags is constant.
[0203] 6. With respect to any one of the aforementioned items,
[0204] A method in which the specific hybridization of the read molecule for the cassette is determined by the identity of the barcode region.
[0205] 7. With respect to any one of the aforementioned items,
[0206] A method in which the above detection molecule is a fluorescent molecule.
[0207] 8. With respect to any one of the aforementioned items,
[0208] A method in which the above detection is performed using a fluorescence microscope.
[0209] 9. With respect to any one of the aforementioned items,
[0210] A method in which the detection molecule comprises biotin, amine, metal, anchor molecule, or acrideite.
[0211] 10. With respect to any one of the aforementioned items,
[0212] A method in which the above detection is performed at least at a single-cell resolution.
[0213] 11. With respect to any one of the aforementioned items,
[0214] A method comprising the step (b) of contacting the sample with at least four read molecules.
[0215] 12. With respect to any one of the aforementioned items,
[0216] A method comprising the step (b) of contacting the sample with a group of read molecules collectively comprising at least three distinguishable detection molecules.
[0217] 13. With respect to any one of the aforementioned items,
[0218] A method comprising the step (b) of contacting the sample with a group of read molecules collectively comprising at least four distinguishable detection molecules.
[0219] 14. With respect to any one of the aforementioned items,
[0220] A method in which at least two target molecules are analyzed simultaneously.
[0221] 15. With respect to any one of the aforementioned items,
[0222] A method in which at least three target molecules are analyzed simultaneously.
[0223] 16. With respect to any one of the aforementioned items,
[0224] A method in which at least 10 target molecules are analyzed simultaneously.
[0225] 17. With respect to any one of the aforementioned items,
[0226] A method in which at least 20 target molecules are analyzed simultaneously.
[0227] 18. With respect to any one of the aforementioned items,
[0228] A method in which the target molecule is a nucleic acid, polypeptide, cell surface molecule, or inorganic material.
[0229] 19. With respect to any one of the aforementioned items,
[0230] A method in which the target molecule is DNA or mRNA.
[0231] 20. In any one of the aforementioned items,
[0232] A method in which the above sample is a cell, cell culture, or tissue sample.
[0233] 21. A system for analyzing at least one target molecule in a sample, wherein the system comprises:
[0234] a. A detector capable of detecting at least two detectable molecules;
[0235] b. As at least one oligonucleotide tag, each oligonucleotide tag is,
[0236] i. A recognition domain that specifically binds to a target molecule to be analyzed, and
[0237] ii. A street comprising at least one cassette, wherein each cassette is,
[0238] 1. A street comprising a barcode region containing at least one nucleotide, wherein an anchor region is adjacent to at least one side.
[0239] Including;
[0240] The street of each oligonucleotide tag is distinguished from the street of another oligonucleotide tag in (b) at least in that A. the spatial order of the cassettes within the street is different, or B. the sequence of the barcode region is different from the barcode region of another oligonucleotide tag in (b).
[0241] Oligonucleotide tags; and
[0242] c. At least two read molecules, each read molecule being
[0243] i. An oligonucleotide that specifically hybridizes with the cassette of at least one oligonucleotide tag used in (b); and
[0244] ii. Containing a detection molecule;
[0245] A read molecule wherein the at least two read molecules collectively comprise at least two distinguishable detection molecules;
[0246] Includes,
[0247] A system wherein a sample is in contact with at least one oligonucleotide tag and at least two read molecules, and the relative spatial order of detection molecules hybridized to at least one oligonucleotide tag is detected, wherein the at least one oligonucleotide tag is hybridized to at least one target molecule, thereby enabling identification of which oligonucleotide tag is hybridized to the target molecule at the corresponding location based on the relative spatial order of the detection molecules.
[0248] Examples
[0249] Example 1
[0250] Compared to existing technologies, the methods and compositions described herein provide a more global and complete view of cellular processes by allowing the analysis of DNA, mRNA, proteins, etc., using a microscope at the single-cell level by utilizing OligoCASSEQ, a multiplexing technology, to visualize and identify thousands of targets within the same cell. Unlike current microscopy techniques, which are limited to analyzing 4-5 targets at a time, OligoCASSEQ achieves a high level of multiplexing in an efficient and cost-effective manner. First, OligoCASSEQ does not use enzymes, which can be costly and inefficient. Second, OligoCASSEQ does not require long oligos, which increase costs but decrease accuracy.
[0251] The technology described herein, sometimes referred to as "OligoCASSEQ," is a technology that enables highly multiplexed target identification at the single-cell level. In this exemplary embodiment, DNA is targeted by an oligopaint having a "street" containing a "cassette" (e.g., Fig. 1a (Reference). The cassette consists of a variable barcode area with a fixed anchor area attached to each side (e.g., Fig. 1b (Reference). Barcodes are sequenced using fluorescently labeled oligos specific to nucleotides at each barcode location (e.g., readouts, also called read molecules) (e.g., Fig. 1c (Reference). The reader recognizes the cassette through the anchor region and competitively combines. Complementary combination is determined by the reader's recognition of a specific barcode sequence (e.g., Fig. 1d (Reference). This design makes the cassette compact and can reduce the amount of readings required. A 5-nucleotide barcode is 1024 (4 5 Can distinguish ) targets.
[0252] OligoCASSEQ complements oligopaint technology. That is, OligoCASSEQ can multiplex / decode anything tagged with an oligonucleotide, which may include, but is not limited to, oligonucleotide-tagged oligos (e.g., oligopaints or any other DNA-binding entity), oligonucleotide-tagged antibodies (e.g., nanobodies), oligonucleotide-tagged small molecules (e.g., for drug screening purposes), oligonucleotide-tagged cells, and oligonucleotide-tagged non-biological materials (metals, chemicals, etc.). DNA targets hybridize with oligonucleotides. The key difference is that when using OligoCASSEQ, nucleotide cassette sequences are encoded as oligonucleotide non-genome target "streets." These cassettes enable barcoding of oligonucleotides, thereby allowing for a high level of multiplexing.
[0253] Targets, such as those described in this specification, may be DNA. OligoCASSEQ can also be applied to other targets (e.g., RNA, proteins, etc.). OligoCASSEQ enables the identification of numerous targets through a microscope. These targets include, but are not limited to, DNA, RNA, proteins, cells, and inorganic materials.
[0254] In this specification, in place ( in-situ ) Demonstrates the use of OligoCASSEQ for tracking chromosomes. As a non-limiting example, using OligoCASSEQ to track human chromosome 2 (Chr. 2; e.g., FIGS. 1e to 1h The localization of five loci can be determined by following the reference. A 2-nucleotide 4-color barcode was used (e.g., Fig. 1e(Reference). Microscopic images of PGP1-F cells show OligoCASSEQ scans at two barcode locations (e.g., see top and middle sections), followed by a re-scan for the first location on the same nucleus (e.g., see bottom section). The schematics above each micrograph indicate the color coding of specific loci at different barcode locations (e.g., Fig. 1f (Reference). The read value on the barcode was identified and then decoded (e.g., Figure 1g (See reference). Then, the spatial location of each chromosome was tracked (e.g., Fig. 1h reference).
[0255] OligoCASSEQ addresses the need to target and identify multiple (>5) targets at once. Since microscopes can only distinguish 4-5 colors at a time, currently only 4-5 targets can be studied simultaneously. OligoCASSEQ solves this problem through barcoding and multiplexing. Instead of representing targets as a single color, targets are displayed in a sequence of four colors, exponentially increasing the number of targets that can be inspected.
[0256] OligoCASSEQ is superior to others because 1) it does not require enzymes, 2) the oligo length is reduced, and 3) the complexity and number of oligos required for reading are reduced.
Claims
Claim 1 A method for analyzing at least one target molecule in a sample, wherein the method comprises: a. contacting the sample with oligonucleotide tags, wherein each oligonucleotide tag comprises i. a recognition domain that specifically binds to the target molecule to be analyzed, and ii. at least one street comprising cassettes, and each cassette comprises 1. a barcode region comprising at least one nucleotide, each side of which is flanked by an anchor region, wherein the anchor regions of the oligonucleotide tags are specific to a set of cassettes and complementary to an anchor hybridization region of at least one read molecule, wherein the street of each oligonucleotide tag is distinguished from the streets of other oligonucleotide tags of step a in that A. the spatial order of the cassettes within the street is different, or B. the sequence of the barcode region is different from the barcode regions of other oligonucleotide tags of step a. b. contacting the sample with at least two read molecules, wherein each read molecule is i. A method comprising: ii. an oligonucleotide that specifically hybridizes with a cassette of at least one oligonucleotide tag among the oligonucleotide tags used in step a, wherein the oligonucleotide comprises anchor hybridization regions adjacent to a barcode hybridization region; ii. a detection molecule, wherein the at least two read molecules collectively comprise at least two distinguishable detection molecules; and c. a step of detecting the relative spatial order of the detection molecules hybridized to the oligonucleotide tags, wherein the oligonucleotide tags are hybridized to at least one target molecule, and thus the relative spatial order of the detection molecules enables identification of which oligonucleotide tag is hybridized to the target molecule at a given location. Claim 2 The method of claim 1, wherein the barcode region comprises 1 to 10 nucleotides. Claim 3 A method according to claim 1 or claim 2, wherein the street comprises at least three cassettes. Claim 4 delete Claim 5 delete Claim 6 A method according to claim 1 or claim 2, wherein the specific hybridization of a read molecule for a cassette is determined by the nucleotide sequence of the barcode region. Claim 7 A method according to claim 1 or claim 2, wherein the detection molecule is a fluorescent group. Claim 8 A method according to claim 1 or claim 2, wherein the detection is performed using a fluorescence microscope. Claim 9 A method according to claim 1 or claim 2, wherein the detection molecule comprises biotin, amine, metal, anchor molecule, or acrideite. Claim 10 A method according to claim 1 or claim 2, wherein the detection is performed at least at a single-cell resolution. Claim 11 A method according to claim 1 or claim 2, wherein step b comprises the step of contacting the sample with at least four read molecules. Claim 12 A method according to claim 1 or claim 2, wherein step b comprises contacting the sample with a group of read molecules collectively comprising at least three distinguishable detection molecules. Claim 13 A method according to claim 1 or claim 2, wherein step b comprises contacting the sample with a group of read molecules collectively comprising at least four distinguishable detection molecules. Claim 14 A method according to claim 1 or claim 2, wherein at least two target molecules are analyzed simultaneously. Claim 15 A method according to claim 1 or claim 2, wherein at least three target molecules are analyzed simultaneously. Claim 16 A method according to claim 1 or claim 2, wherein at least 10 target molecules are analyzed simultaneously. Claim 17 A method according to claim 1 or claim 2, wherein at least 20 target molecules are analyzed simultaneously. Claim 18 delete Claim 19 A method according to claim 1 or claim 2, wherein the target molecule is DNA or mRNA. Claim 20 A method according to claim 1 or claim 2, wherein the sample is a cell, a cell culture, or a tissue sample. Claim 21 A system for analyzing at least one target molecule in a sample, wherein the system comprises: a. a detector capable of detecting at least two detectable molecules; b. oligonucleotide tags, each oligonucleotide tag comprising: i. a recognition domain that specifically binds to the target molecule to be analyzed; and ii. a street comprising cassettes, wherein each cassette comprises:
1. a barcode region comprising at least one nucleotide, each side of which is flanked by an anchor region, wherein the anchor regions of the oligonucleotide tags are specific to a set of cassettes and complementary to an anchor hybridization region of at least one read molecule; and wherein the street of each oligonucleotide tag comprises at least A. oligonucleotide tags that are distinguished from the street of other oligonucleotide tags in that the spatial order of the cassettes within the street is different or B. the sequence of the barcode region is different from the barcode regions of other oligonucleotide tags of b; and c. at least two read molecules, wherein each read molecule comprises: i. b. A system comprising an oligonucleotide that specifically hybridizes with a cassette of at least one oligonucleotide tag among the oligonucleotide tags, wherein the oligonucleotide comprises anchor hybridization regions adjacent to a barcode hybridization region, and ii. a detection molecule, wherein the at least two reading molecules comprise reading molecules that collectively include at least two distinguishable detection molecules; a sample is in contact with the oligonucleotide tags and at least two reading molecules, and the relative spatial order of the detection molecules hybridized to the oligonucleotide tags is detected, wherein the oligonucleotide tags are hybridized to at least one target molecule, and accordingly the relative spatial order of the detection molecules enables identification of which oligonucleotide tag is hybridized to the target molecule at a corresponding location.
Citation Information
Patent Citations
Methods for detecting and identifying genomic nucleic acids
WO2017161251A1
Sequential probing of molecular targets based on pseudo-color barcodes with embedded error correction mechanism
WO2018026873A1
